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A B S T R A C T
Background
This is an update of a Cochrane review that was first published in 2011 of the effects of reducing dietary salt intake, through advice to
reduce salt intake or low-sodium salt substitution, on mortality and cardiovascular events.
Objectives
1. To assess the long-term effects of advice and salt substitution, aimed at reducing dietary salt, on mortality and cardiovascular
morbidity.
2. To investigate whether a reduction in blood pressure is an explanatory factor in the effect of such dietary interventions on mortality
and cardiovascular outcomes.
Search methods
We updated the searches of CENTRAL (2013, Issue 4), MEDLINE (OVID, 1946 to April week 3 2013), EMBASE (OVID, 1947 to
30 April 2013) and CINAHL (EBSCO, inception to 1 April 2013) and last ran these on 1 May 2013. We also checked the references
of included studies and reviews. We applied no language restrictions.
Selection criteria
Trials fulfilled the following criteria: (1) randomised, with follow-up of at least six months, (2) the intervention was reduced dietary salt
(through advice to reduce salt intake or low-sodium salt substitution), (3) participants were adults and (4) mortality or cardiovascular
morbidity data were available. Two review authors independently assessed whether studies met these criteria.
Data collection and analysis
A single author extracted data and assessed study validity, and a second author checked this. We contacted trial authors where possible
to obtain missing information. We extracted events and calculated risk ratios (RRs) and 95% confidence intervals (CIs).
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Main results
Eight studies met the inclusion criteria: three in normotensives (n = 3518) and five in hypertensives or mixed populations of normo-
and hypertensives (n = 3766). End of trial follow-up ranged from six to 36 months and the longest observational follow-up (after trial
end) was 12.7 years.
The risk ratios (RR) for all-cause mortality in normotensives were imprecise and showed no evidence of reduction (end of trial RR
0.67, 95% confidence interval (CI) 0.40 to 1.12, 60 deaths; longest follow-up RR 0.90, 95% CI 0.58 to 1.40, 79 deaths n=3518) or
in hypertensives (end of trial RR 1.00, 95% CI 0.86 to 1.15, 565 deaths; longest follow-up RR 0.99, 95% CI 0.87 to 1.14, 674 deaths
n=3085).
There was weak evidence of benefit for cardiovascular mortality (hypertensives: end of trial RR 0.67, 95% CI 0.45 to 1.01, 106 events
n=2656) and for cardiovascular events (hypertensives: end of trial RR 0.76, 95% CI 0.57 to 1.01, 194 events, four studies, n = 3397;
normotensives: at longest follow-up RR 0.71, 95% CI 0.42 to 1.20, 200 events; hypertensives: RR 0.77, 95% CI 0.57 to 1.02, 192
events; pooled analysis of six trials RR 0.77, 95% CI 0.63 to 0.95, n = 5912). These findings were driven by one trial among retirement
home residents that reduced salt intake in the kitchens of the homes, thereby not requiring individual behaviour change.
Advice to reduce salt showed small reductions in systolic blood pressure (mean difference (MD) -1.15 mmHg, 95% CI -2.32 to 0.02
n=2079) and diastolic blood pressure (MD -0.80 mmHg, 95% CI -1.37 to -0.23 n=2079) in normotensives and greater reductions
in systolic blood pressure in hypertensives (MD -4.14 mmHg, 95% CI -5.84 to -2.43 n=675), but no difference in diastolic blood
pressure (MD -3.74 mmHg, 95% CI -8.41 to 0.93 n=675).
Overall many of the trials failed to report sufficient detail to assess their potential risk of bias. Health-related quality of life was assessed
in one trial in normotensives, which reported significant improvements in well-being but no data were presented.
Authors’ conclusions
Despite collating more event data than previous systematic reviews of randomised controlled trials, there is insufficient power to
confirm clinically important effects of dietary advice and salt substitution on cardiovascular mortality in normotensive or hypertensive
populations. Our estimates of the clinical benefits from advice to reduce dietary salt are imprecise, but are larger than would be predicted
from the small blood pressure reductions achieved. Further well-powered studies would be needed to obtain more precise estimates.
Our findings do not support individual dietary advice as a means of restricting salt intake. It is possible that alternative strategies that
do not require individual behaviour change may be effective and merit further trials.
P L A I N L A N G U A G E S U M M A R Y
Reduced dietary salt for the prevention of cardiovascular disease
Cardiovascular disease includes heart attacks and strokes and is a major cause of premature death and disability. This is an update of
a review first published in 2011. This review sets out to assess whether intensive support and encouragement to cut down on salt in
foods, and substituting low-sodium salt, reduces the risk of death or cardiovascular disease. This update includes two new studies and
eliminates one problematic study, giving a total of eight trials with 7284 participants.
Dietary advice and salt substitution did reduce the amount of salt eaten, which led to a small reduction in blood pressure by six months.
There was weak evidence of benefit for cardiovascular events, but these findings were inconclusive and were driven by a single trial
among retirement home residents, which reduced salt intake in the kitchens of the homes.
The findings of our review do not mean that advising people to reduce salt should be stopped. However, additional measures - reducing
the amount of hidden salt in processed foods, for example - will make it much easier for people to achieve a lower salt diet. Overall
many of the trials failed to report sufficient detail to assess their potential risk of bias. Further evidence of the effects of different ways
of reducing dietary salt on clinical events is needed from experimental and observational studies to underpin public health policies.
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B A C K G R O U N D
In 2010 it was estimated that nearly 12.9 million deaths (a quarter
of the global total) were due to ischaemic heart disease and stroke
(Lozano 2012).Morbidity data aremore difficult to collect because
there are so many different measures of cardiovascular morbidity.
However, in 2010 ischaemic heart disease was globally the number
one cause of disability adjusted life years (DALYs) lost each year,
with nearly 130 million DALYs (Allender 2008). Similarly, high
blood pressure was the number one risk factor, with over 170
million DALYs lost globally each year (Murray 2013).
Globally, high blood pressure is a leading risk factor for cardiovas-
cular disease, contributing over 7% of the global DALYs in 2010
(Lim 2012). The relationship of salt intake to blood pressure is the
basis for the belief that restriction of dietary sodium intake will
prevent blood pressure-related cardiovascular events (Elliot 1996).
The public health recommendations of a decade ago remain in
place: to reduce salt intake by about half, i.e. from approximately
10 to 5 g/day (Dietary Guidelines for Americans 2010; He 2010;
SACN 2003; Whelton 2002; Whelton 2012), and they have also
been endorsed in current World Health Organization guidelines
on sodium intake (WHO 2012).
Data from observational studies have indicated that a high di-
etary intake of salt is an important risk factor for cardiovascular
disease (He 2002; He 2010). Short-term intervention studies, in-
cluding the Dietary Approaches to Stop Hypertension (DASH)
trials, have shown decreases in systolic blood pressure in all groups
(Sacks 2001). Thiswas confirmedby a systematic review andmeta-
analysis of 13 prospective studies including 177,000 participants,
which reported a greater risk of stroke in those with higher salt in-
takes (relative risk 1.23, 95% CI 1.06 to 1.43) (Strarzzullo 2009).
However, in this review the association between salt intake and
all cardiovascular events was smaller (relative risk 1.14, 95% CI
0.99 to 1.31) and with the exclusion of one study statistical sig-
nificance was achieved (relative risk 1.17, 95% CI 1.02 to 1.32),
but all-cause mortality was not reported. The interpretation of this
observational evidence base is complicated by the heterogeneity
in estimating sodium intake (diet or urinary salt excretion), types
of participants (healthy, hypertensive, obese and non-obese), end-
points and the definition of outcomes across studies (Alderman
2010). A more recent review of observational studies reported no
strong evidence of an effect on all-cause mortality (relative risk
1.06, 95% CI 0.94 to 1.20) and similar inconclusive effects on
cardiovascular disease (relative risk 1.12, 95% CI 0.93 to 1.34),
noting that the quality of evidence was generally low due to non-
randomised designs (Aburto 2013).
Following publication of the 2011 Cochrane review, commenta-
tors have put forward a view that the relationship between dietary
sodium intake and cardiovascular events may be J-shaped, sug-
gesting that lowering sodium beyond a certain point may not be
beneficial (Alderman 2011; Alderman 2012;Mente 2013). Several
prospective cohort studies have been published recently that over-
come the problem of dietary sodium assessment by using urinary
sodium excretion as an index of dietary intake. These have shown
a possible J-shaped relationship: low sodium intake (< 3 g/day) is
associatedwith no lower rate of cardiovascular disease, and perhaps
a higher rate (Ekinci 2011; O’Donnell 2011; Stolarz-Skrzypek
2011). In light of these studies, the US Institute of Medicine re-
viewed the evidence and found that it supported population-based
efforts to lower excessive dietary salt intake, but not the lowering
of intakes to < 2.3 g sodium/day (Institute of Medicine 2013).
Commentary on the new recommendations has suggested that the
scientific debates, our earlier Cochrane review and difficulties in
interpreting the evidence only provide opportunities for the food
industry to avoid regulation of salt in their products (Neal 2013).
Others consider that we still have insufficient evidence to decide
whether to advise people to reduce their salt intake below current
average levels (Mente 2013). A recent review of four decades of the
salt and health debate concludes that the evidence available from
different eras has been unable to resolve the debate satisfactorily
(Bayer 2012).
A number of meta-analyses of randomised controlled trials of salt
reduction and blood pressure have been undertaken (He 2004;
Jürgens 2004). Whilst these analyses consistently report a reduc-
tion in the level of blood pressure with reduced salt intake, the level
of blood pressure reduction achieved is less impressive in the longer
term. The 2004 Cochrane review of dietary salt restriction inter-
vention studies of at least sixmonths’ duration found that intensive
support and encouragement to reduce salt intake lowered blood
pressure at 13 to 60 months, but only by a small amount (systolic
by 1.1 mmHg, 95% CI 1.8 to 0.4; diastolic by 0.6 mmHg, 95%
CI 1.5 to -0.3) (Hooper 2004). These findings of small blood pres-
sure reductions among normotensive people were confirmed in a
recent Cochrane review, which demonstrated much smaller blood
pressure reductions in normotensives (about 1% in systolic blood
pressure) and greater reductions in hypertensive people (around
3.5%) (Graudal 2011). Certainly the very large estimated effects
of salt reduction using both trial and observational data are no
longer considered plausible (Law 1991). The most recent review
has continued the questionable practice of combining both short
and longer duration trials: among 34 trials of 3230 participants
with four or more weeks (median four to five weeks) of follow-up,
the mean change in blood pressure was -4 mmHg for systolic and
-2mmHg for diastolic blood pressure, although heterogeneity was
marked with I² estimates of between 68% and 75% (He 2013a;
He 2013b). Such estimates are unlikely to reflect the reductions in
blood pressure that can be obtained in the general normotensive
population in practice. However, even small sustained reductions
in mean blood pressure of 2 to 3 mmHg would be sufficient for
important population reductions in cardiovascular events (Elliot
1991).
In a previous version of this review a trial of salt restriction in
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patients with heart failure was included (Paterna 2008). We have
now excluded this trial following the retraction by the editors of
Heart journal of ameta-analysis including this paper (Editor’s Note
2013). Trials of salt restriction in heart failure are no longer within
the scope of this review.
Whilst our earlier Cochrane review also sought to assess the impact
of dietary salt restriction advice on mortality and cardiovascular
events, across the 11 randomised controlled trials included there
were only 17 deaths spread evenly across groups and 46 cardiovas-
cular events in the controls compared with 36 in the low-sodium
diet groups (Hooper 2004). The small number of events limited
the ability of this earlier review to detect small to moderate reduc-
tions in the risk of cardiovascular events.
Given that the effect of interventions to reduce dietary salt on
blood pressure is well established and health policy in the area of
salt reduction has advanced, the primary focus of this review is to
confirm whether reducing dietary salt through advice or substitu-
tion is associated with improvements in mortality and cardiovas-
cular events.
O B J E C T I V E S
1. To assess the long-term effects of advice and salt
substitution, aimed at reducing dietary salt, on mortality and
cardiovascular morbidity.
2. To investigate whether a reduction in blood pressure is an
explanatory factor in the effect of such dietary interventions on
mortality and cardiovascular outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), individual or cluster level,
with follow-up of at least six months.
Types of participants
Studies in adults (18 years or older), irrespective of gender or eth-
nicity. We excluded studies in patients with heart failure, children
or pregnant women.
Types of interventions
Reducing dietary salt intake, either by advice from health pro-
fessionals or provision of low-sodium salt substitution. The com-
parison group could include usual, control or placebo diet, or no
intervention.
Types of outcome measures
Primary outcomes
1. All-cause mortality.
2. Cardiovascular mortality.
3. Cardiovascular morbidity (including fatal and non-fatal
myocardial infarction, stroke, angina, heart failure, peripheral
vascular events, sudden death, revascularisation (coronary artery
bypass surgery or angioplasty with or without stenting) and
cardiovascular-related hospital admissions).
We assessed primary outcomes at study end and also at the latest
trial follow-up, where participants had been followed observation-
ally after the end of the original trial.
Secondary outcomes
In studies that reported the primary outcomes we also sought the
following secondary outcomes:
1. Changes in systolic and diastolic blood pressure.
2. Urinary salt excretion (or other method of estimation of salt
intake).
3. Health-related quality of life using a validated outcome
measure (e.g. Short Form 36, McHorney 1993).
Search methods for identification of studies
Electronic searches
We updated the searches, initially run in 2008 (Appendix 1), and
re-ran these on 1 May 2013 (Appendix 2). We searched the fol-
lowing databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2013, Issue 4);
• MEDLINE (OVID, 1946 to April week 3 2013);
• EMBASE Classic + EMBASE (OVID, 1947 to 30 April
2013);
• CINAHL Plus with Full Text (EBSCO, to 1 April 2013);
• PsycINFO (OVID, 1806 to October 2008 - not updated as
resources were limited);
• Health Technology Assessment (HTA) on The Cochrane
Library (2008, Issue 4 - not updated as resources were limited);
• Database of Abstracts of Reviews of Effects (DARE) on The
Cochrane Library (2008, Issue 4 - not updated as resources were
limited).
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Searches conducted in MEDLINE, EMBASE, CINAHL and
PsycINFO included a controlled trials filter in 2008. We updated
this in 2013 to the Cochrane sensitivity-maximising RCT filter
for MEDLINE and adaptations of it for EMBASE and CINAHL
(Lefebvre 2011). We limited the searches in MEDLINE, EM-
BASE and CINAHL by entry dates/weeks to identify only newly
added records since the last search. We limited the CENTRAL
search by publication dates.
We applied no language restrictions.
Searching other resources
We searched reference lists of all eligible trials and relevant system-
atic reviews for additional studies.
Data collection and analysis
Selection of studies
Two authors (KA and RST) independently screened the titles and
abstracts of studies identified by the original search and discarded
clearly irrelevant studies. In order to be selected, abstracts had to
identify clearly the study design, an appropriate population and a
relevant intervention/exposure, as described above. We obtained
the full-text reports of all potentially relevant studies and two au-
thors (KA and RST) assessed these independently for eligibility,
based on the defined inclusion criteria. We resolved any disagree-
ment by discussion or where agreement could not be reached, by
consultation with an independent third person (LH). For the up-
date, two authors (AJA, FCT or NM) independently screened half
the abstracts. A third author (NM) checked 10% of all studies.
Two authors (AJA and FCT) checked full-text articles of poten-
tially relevant studies. A third author (NM) checked all excluded
studies.
Data extraction and management
We used standardised data extraction forms.We extracted relevant
data regarding inclusion criteria (study design, participants, inter-
vention/exposure and outcomes), risk of bias (see below) and out-
come data. A single author (KA or RST) carried out data extrac-
tion and a second author (RST or KA) checked this. We resolved
disagreements by discussion or, if necessary, with a third author
(LH). We extracted outcomes at the latest follow-up point within
the trial, and also at the latest follow-up after the trial where this
was available, as we reasoned this would maximise the number of
events reported.We contacted all included study authors to clarify
any missing outcome data or issues of ’Risk of bias’ assessment.
For the update, two authors (AJA or FCT and SE) carried out data
extraction independently.
Assessment of risk of bias in included studies
Factors considered included random sequence generation and al-
location concealment, description of drop-outs and withdrawals,
blinding (participants, personnel and outcome assessment) and
selective outcome reporting. In addition we sought evidence that
the groups were balanced at baseline, that intention-to-treat anal-
ysis was undertaken and that the period over which the salt inter-
vention lasted and follow-up of outcome were equivalent. A single
author (KA) assessed the risk of bias of the included studies and a
second author (RST) checked this. We resolved disagreements by
discussion or if necessary with a third author (LH). Two authors
(AJA and FCT) independently checked risk of bias in the update.
Data synthesis
We processed data as described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). For mortality and
cardiovascular events, we calculated the risk ratio and 95% confi-
dence interval (CI) for each trial. For blood pressure and urinary
sodium excretion, we calculated mean group differences and 95%
CI using the mean difference.We explored heterogeneity amongst
included studies qualitatively (by comparing the characteristics of
included studies) and quantitatively (using the Chi² test of hetero-
geneity and the I² statistic). We combined results from included
studies for each outcome to give an overall estimate of treatment ef-
fect at the latest point available within the randomised trial and, as
a secondary analysis, at the latest point available (including where
participants were followed up after the end of the randomisation
period). We used a fixed-effect meta-analysis except where statisti-
cal heterogeneity was identified (Chi² P value ≤ 0.05 and I² value
≥ 50%), in which case we considered methodological and clinical
reasons for heterogeneity and used a random-effects model.
Subgroup analysis and investigation of heterogeneity
We planned to use stratified meta-analysis to explore the differen-
tial effects that might occur as a result of: individual advice versus
group advice, salt substitution versus advice and baseline risk of
cardiovascular disease. We used meta-regression to assess the ef-
fects of the level of salt reduction achieved, baseline blood pres-
sure and change in blood pressure on mortality and cardiovascular
event outcomes.
Sensitivity analysis
We conducted sensitivity analysis of the primary outcomes to de-
termine whether cluster and individually randomised trial designs
influenced the effects observed.
R E S U L T S
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Description of studies
Results of the search
The searches in 2013 retrieved 2439 references and 1861 remained
after de-duplication.We excluded1737 references based on screen-
ing the title and abstract. We retrieved the remaining 124 refer-
ences in full text, two of which met the inclusion criteria (two
reports) (CSSS 2007; Kwok 2012). We also identified three addi-
tional reports for previously included studies.
The searches in 2008 identified a total of 2649 titles, of which
we excluded 2605 on title and abstract. After examining the full
texts of the remaining 44 papers, we included six trials (26 reports)
(Chang 2006; HPT 1990; Morgan 1978; TOHP I 1992; TOHP
II 1997; TONE 1998).
Five studies from an earlier Cochrane review, Hooper 2004, met
the inclusion criteria (HPT 1990; Morgan 1978; TOHP I 1992
(18 months); TOHP II 1997; TONE 1998). We excluded the
other six included studies from Hooper 2004, as they did not
report mortality or cardiovascular events (Alli 1992; Arroll 1995;
Costa 1981; Morgan 1987; Silman 1983; Thaler 1982).
In total, we included eight trials (reported in 31 papers) and one
ongoing study (Aung 2012).
We obtained responses to our requests for additional details from
four of the included trial authors (Kwok 2012; TOHP I 1992;
TOHP II 1997; TONE 1998).
The study selection process is summarised in the flow diagram
shown in Figure 1.
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Figure 1. 578Study flow diagram for review and update
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Included studies
The eight included studies are described in the Characteristics of
included studies table.
We included three trials in people with normotension (n = 3518)
(HPT 1990; TOHP I 1992; TOHP II 1997), two in people with
hypertension (n = 748) (Morgan 1978; TONE 1998), and three
in a mixed population of people with normo- and hypertension (n
= 3018) (Chang 2006; CSSS 2007; Kwok 2012). For the purposes
of analysis, we included studies in mixed normo- and hypertensive
individuals with the hypertensive studies.
Post-randomisation follow-up varied from up to six to nine
months (Morgan 1978), to around three-years (Chang 2006;HPT
1990), and long-term post-trial end follow-up of 10 to 15 years
(TOHP I 1992; TOHP II 1997; TONE 1998).
The three normotensive trials were in healthy people (predom-
inantly white (> 75%), male (75%), median age 40) and were
conducted in the USA. Entry criteria varied between trials, but
included those with diastolic blood pressure from 78 mmHg to
89 mmHg, with a narrow range of means from 83 mmHg to
86 mmHg diastolic and 124 mmHg to 127 mmHg systolic. The
number of participants included ranged from 392 to 2382.
All three trials in normotensives (as well as TONE 1998, be-
low) aimed to reduce salt by comprehensive dietary and behaviour
change programmes led by experienced personnel, including reg-
ular group counselling sessions over several months, with newslet-
ters between sessions, self assessment, goal setting, food tasting and
recipes. For example, the Hypertension Prevention Trial (HPT)
ran 10 weekly group counselling sessions on food selection, food
preparation and behaviour management skills, followed by semi-
monthly and then bi-monthly meetings throughout the trial (with
newsletters in the months where no meetings occurred) (HPT
1990). Sessions were run by nutritionists and behavioural scien-
tists and individual counselling was provided, where participants
missed sessions or had special needs. Techniques used in the ses-
sions included group discussions, instructions for dietary record
keeping, goal setting, individual diet analysis for each participant,
cooking demonstrations, provision of recipe books and tasting of
new foods. The intervention duration ranged from seven months
(TONE 1998) to 36 months (TOHP II 1997). Control groups
received no active intervention. Sodium excretion goals were set
at less than 70 to 80 mmol/24 hours. Only two studies used salt
substitution; one gradually increased the use of a potassium-en-
riched salt substitute over several weeks, although this was done
in kitchens by cooks without requiring participants to alter their
behaviours (Chang 2006), and the other advised participants to
use a low-sodium salt substitute (CSSS 2007).
The five trials that included hypertensives included one trial in
treated hypertensive participants (TONE 1998), two that in-
cluded participants with untreated hypertension (Chang 2006;
Morgan 1978), one study with a proportion of treated participants
(CSSS 2007) and one unspecified (Kwok 2012). In the mixed
studies, the per cent with hypertension ranged from 40% (Chang
2006) to 60% (Kwok 2012). Studies were carried out in Australia,
China, Hong Kong,Taiwan and the USA and ranged in size from
77 to 1981 participants. Between 15% and 100% of participants
were male, with a median age of 60 years.Most studies did not re-
port ethnicity. At study entrymean diastolic blood pressure ranged
from 71 mmHg (Chang 2006; TONE 1998, on treatment) to
97 mmHg (Morgan 1978, untreated) and systolic blood pressure
ranged from approximately 131 mmHg (Chang 2006, untreated;
TONE 1998, on treatment) to 162 mmHg (Morgan 1978, un-
treated).
Sodium goals varied from < 80 mmol/day (TONE 1998) to 70 to
100 mmol/day and unspecified sodium intake (Chang 2006).
Excluded studies
Studies that were close to meeting but did not meet our inclusion
criteria are listed in the Characteristics of excluded studies table.
Risk of bias in included studies
A number of studies failed to give sufficient detail to assess their
potential risk of bias.
Details of the generation and concealment of the random alloca-
tion sequence were particularly poorly reported (Figure 2; Figure
3). However, in all cases there was objective evidence of balance
in the baseline characteristics of the intervention and control par-
ticipants.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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For blinding of outcome assessment we assumed there to be low
risk of bias, as the primary outcomes of mortality and major car-
diovascular disease morbidity are unlikely to be wrongly assessed
based on participant allocation.
While studies reported loss to follow-up and reasons for loss to
follow-up, only a few undertook a sensitivity or imputation anal-
ysis to assess the impact of these losses, followed up participants
for event outcomes and described reasons for loss to follow-up
for other outcomes. In the Trial of Nonpharmacologic Interven-
tion in the Elderly (TONE) trial, the authors stated that data
were collected via psychological questionnaires at randomisation
and a number of the follow-up visits (TONE 1998). However,
none of these data were found in the trial reports. Although often
not stated, all studies appeared to undertake an intention-to-treat
analysis in that groups were analysed according to initial random
allocation.
All studies assessed compliancewith the salt reduction intervention
using diet diaries or monitoring of use. However, in the longer-
term post-trial end follow-up of the TOHP I (11.5 years), TOHP
II (eight years) and TONE (12.7 years) trials, such compliance
datawere not reported beyond the official end of the study (TOHP
I 1992; TOHP II 1997; TONE 1998). Therefore it was unclear
whether intervention groups were encouraged to continue their
low-salt diets long-term, or returned to their pre-trial diet. Simi-
larly, in the control groups it is not clear whether they were left to
continue with their usual diet or advised to reduce their salt at the
end of the trial.
Effects of interventions
Given the heterogeneity of populations and the likelihood that
normotensives and hypertensives would differ in their adherence
to dietary interventions, the results are presented and pooled sepa-
rately for studies of people with normotension and hypertension.
We pooled outcomes at end of trial and at the longest follow-up
point unless otherwise indicated.
Primary outcomes
All-cause mortality
All-cause mortality was reported at the end of the trial in seven of
the included studies (Chang 2006; CSSS 2007; HPT 1990; Kwok
2012; Morgan 1978; TOHP I 1992; TOHP II 1997). Trials were
homogeneous and therefore we pooled them using a fixed-effect
model. There was no strong evidence of a reduction in the num-
ber of deaths in the reduced salt group relative to controls for the
normotensive (fixed-effect risk ratio (RR) 0.67, 95% confidence
interval (CI) 0.40 to 1.12, 60 deaths in total, I² = 0%) or hyper-
tensive populations (fixed-effect RR 1.00, 95% CI 0.86 to 1.15,
565 deaths in total, I² = 0%) (Analysis 1.1).
A longer observational follow-up following the end of the ran-
domised trial period was reported for the Trials of Hypertension
Prevention (TOHP) I (11.5 years) and TOHP II (eight years) tri-
als (Cook 2007). We were also able to obtain longer observational
unpublished data from the authors from the Trial of Nonphar-
macologic Intervention in the Elderly (TONE) study (12.7 years)
(TONE 1998). Trials remained homogeneous. At longest follow-
up, there was still no evidence of a reduction in the number of
deaths in the reduced salt group relative to controls, for the nor-
motensive (fixed-effect RR 0.90, 95% CI 0.58 to 1.40, 79 deaths
in total, I² = 0%) or hypertensive populations (fixed-effect RR
0.99, 95% CI 0.87 to 1.14, 674 deaths; I² = 0%) (Analysis 1.2).
Cardiovascular mortality
Cardiovascular mortality was reported in three studies including
hypertensive patients. Chang 2006 reported a lower proportion of
cardiovascular deaths in the intervention group than in the control
group (27 versus 66) and contributed 90% weight to this analysis.
Importantly, dietary salt was substituted gradually with a potas-
sium-rich, low-salt product in the kitchens used by residents in
retirement homes. Morgan 1978 reported only one cardiovascular
death in the intervention group and none in the control group,
but in a subsequent publication two cardiovascular deaths were
reported in each of the intervention and control groups (Morgan
1980). There was no difference in the other study (CSSS 2007).
The pooled risk ratio shows weak, inconclusive evidence of benefit
(fixed-effect RR 0.67, 95% CI 0.45 to 1.01, 106 cardiovascular
deaths, I² = 0%) (Analysis 1.3).
Cardiovascular morbidity
We assessed cardiovascular events (both fatal and non-fatal) at end
of trial. The definition of non-fatal cardiovascular events varied
from trial to trial, although it broadly consisted of a composite of
myocardial infarction, stroke, coronary artery bypass and percuta-
neous transluminal coronary angioplasty. Data at end of trial were
only available in trials of hypertensives (Chang 2006; CSSS 2007;
Morgan 1978; TONE 1998), and demonstrated weak evidence
of a reduction in events (fixed-effect RR 0.76, 95% CI 0.57 to
1.01, 192 events, I² = 0%) (Analysis 1.4). Cardiovascular events
at longest follow-up were also examined to maximise the number
of events available for analysis and gain data for normotensives.
Data were available from six trials (Chang 2006; CSSS 2007;HPT
1990; Morgan 1978; TOHP I 1992; TOHP II 1997). Following
long-term observational follow-up, TOHP I and II reported no
strong evidence of risk reduction, with heterogeneity of effect be-
tween the two trials in normotensive participants (random-effects
RR 0.71, 95% CI 0.42 to 1.20, 200 events, I² = 63%). We found
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weak evidence of benefit in hypertensive individuals (fixed-effect
RR0.77, 95%CI 0.57 to 1.02, 192 events, I² = 0%) (Analysis 1.5).
Pooling across normotensive and hypertensive trials gives modest
evidence of benefit for cardiovascular events at longest follow-up
(random-effects RR 0.77, 95% CI 0.63 to 0.95, 392 events, I² =
0%, P value < 0.01).
Secondary outcomes
Changes in systolic and diastolic blood pressure
End of trial blood pressure was reported by five studies (HPT
1990; Morgan 1978; TOHP I 1992; TOHP II 1997; TONE
1998). CSSS 2007 reported end of trial blood pressure but did not
provide standard deviations (SD), so we imputed the median SD
of the other studies to include the findings in the pooled analysis
using themethodology outlined in section 7.7.3.3 of theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Kwok 2012 did not report end of trial blood pressure but stated
that there was no difference between intervention and control
groups. For systolic blood pressure there was evidence of substan-
tial statistical heterogeneity in the normotensive groups, but not
the hypertensive studies. Systolic blood pressure was reduced in
all intervention arms: normotensives (random-effects mean differ-
ence (MD) -1.15 mmHg, 95% CI -2.32 to 0.02, I² = 64%) and
hypertensives (random-effects MD -4.14 mmHg, 95% CI -5.84
to -2.43, I² = 0%). Combining normotensives and hypertensives
resulted in substantial heterogeneity (I² = 74%) and moderate ev-
idence of benefit (random-effects MD -1.79 mmHg, 95% CI -
3.23 to -0.36). Diastolic blood pressure was also reduced in nor-
motensives (random-effects MD -0.80 mmHg, 95% CI -1.37 to
-0.23, I² = 0%), but not in hypertensives (random-effects MD -
3.74 mmHg, 95% CI -8.41 to 0.93, I² = 67%). In this analysis
there was no heterogeneity in normotensives, but substantial het-
erogeneity in hypertensives. Pooled analysis of normotensives and
hypertensives showed moderate evidence of an effect (random-
effects MD -1.17 mmHg, 95% CI -2.08 to -0.26) (Analysis 1.6;
Analysis 1.7).
Urinary salt excretion (or other method of estimation of
salt intake)
Changes in urinary sodium excretion at the end of trial were re-
ported by six studies (HPT 1990; Kwok 2012; Morgan 1978;
TOHP I 1992; TOHP II 1997; TONE 1998). There was sub-
stantial evidence of statistical heterogeneity, which may reflect dif-
ferent approaches to the assessment of 24-hour urinary sodium
excretion. In the study by Morgan, results were only reported as
samples and therefore comprised repeated observations for a num-
ber of patients (Morgan 1978). As for blood pressure, in a number
of studies the last urinary sodium excretion value available was
at a time point much preceding the timing of the reported mor-
tality or cardiovascular events (blood pressure follow-up time: six
months (Morgan 1978); 30 months (TONE 1998); 18 months
(TOHP I 1992); 36 months (TOHP II 1997)). Urinary 24-hour
sodium excretionwas reduced by a similar amount across the study
subgroups: normotensives (random-effects MD -34.19 mmol/24
hours, 95% CI -49.61 to -18.78, I² = 76%); hypertensives (ran-
dom-effectsMD -20.48mmol/24 hours, 95%CI -53.68 to 12.73,
I² = 98%) and pooled analysis (random-effectsMD -27.21 mmol/
24 hours, 95% CI -49.85 to -4.57, I² = 97%) (Analysis 1.8).
Health-related quality of life
One study in normotensives reported that significant improve-
ments on the Psychological General Well-Being scale were ob-
served at six and 18 months, but no data were presented (TOHP
I 1992).
Subgroup analyses and investigation of heterogeneity
In order to take to take account of the heterogeneity in popula-
tions and cardiovascular baseline risk, we stratified meta-analyses
according to whether studies were undertaken in normotensive or
hypertensive populations. As one of the studies involved a kitchen
salt substitution rather than requiring participants to change their
behaviours, we conducted a subgroup analysis excluding this trial
(Chang 2006). This resulted in reductions in the pooled effects
observed (cardiovascular mortality at end of trial: RR 0.87, 95%
CI 0.30 to 2.55; cardiovascular events at end of trial: RR 0.86,
95% CI 0.57 to 1.30; cardiovascular events at longest follow-up:
RR 0.81, 95% CI 0.63 to 1.03). As this trial did not measure
blood pressure or urinary sodium excretion we were not able to
explore its effects on these outcomes.
Small study bias
Given the small number of included studies it was not possible to
assess small study bias either statistically or using a funnel plot.
Sensitivity analysis
We conducted sensitivity analysis for the primary outcomes by
removing the Kwok 2012 and Chang 2006 studies as they were
cluster-randomised trials. Both studies were carried out in hyper-
tensives, so results for normotensives remained unchanged. Chang
2006 was the largest study conducted in hypertensives, so the over-
all result of removing it was to reduce the sample size and con-
siderably decrease the precision of the estimate. For the primary
outcome all-cause mortality at end of trial, the two removed tri-
als had accounted for 86.9% of the weight, thus the sensitivity
analysis increased the relative weight of the TOHP I 1992 and
TOHP II 1997 trials. As a result, even though the pooled estimate
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for hypertensives was higher in sensitivity analysis, the pooled es-
timate was lower than the main analysis but with less precision
(RR 0.73, 95% CI 0.45 to 1.17, 69 events, 4193 participants)
(Analysis 2.1). For cardiovascular mortality, removing the cluster-
randomised trials decreased the effect estimate and decreased the
precision (RR 0.87, 95% CI 0.29 to 2.64, 13 events, 675 partic-
ipants) (Analysis 2.2). For cardiovascular disease events at end of
trial, removing Chang 2006 resulted in TONE 1998 increasing
in weight to 84.5% of the estimate, and resulted in salt reduction
showing less evidence of an effect (RR 0.86, 95% CI 0.57 to 1.30,
101 events, 1416 participants) (Analysis 2.3).
D I S C U S S I O N
Summary of main results
This Cochrane review identified eight randomised controlled tri-
als that assessed the long-term (more than six months) effects of
interventions aimed at reducing dietary salt on mortality and car-
diovascular morbidity. Three trials were in normotensives (HPT
1990; TOHP I 1992; TOHP II 1997, n = 3518 participants),
two in hypertensives (Morgan 1978; TONE 1998, n = 748 par-
ticipants) and three in mixed populations of normo- and hyper-
tensives (Chang 2006; CSSS 2007; Kwok 2012, n = 3018 partic-
ipants).
We found no strong evidence that dietary advice or substitution
to reduce salt intake reduced all-cause mortality in normotensives
(end of trial risk ratio (RR) 0.67, 95% confidence interval (CI)
0.40 to 1.12, 60 deaths, 3518 participants; longest follow-up RR
0.90, 95% CI 0.58 to 1.40, 79 deaths, 3518 participants), or in
hypertensives (end of trial RR 1.00, 95% CI 0.86 to 1.15, 565
deaths, 3085 participants; longest follow-up RR 0.99, 95% CI
0.87 to 1.14, 674 deaths, 3680 participants).
There was weak evidence that cardiovascular mortality and cardio-
vascular events were reduced among hypertensives (cardiovascular
mortality: end of trial RR 0.67, 95% CI 0.45 to 1.01, 106 deaths,
2656 participants; cardiovascular events: end of trial RR 0.76,
95% CI 0.57 to 1.01, 194 deaths, 3397 participants), however
these results were strongly driven by the Chang 2006 study, which
accounted for 88% of the weight in the cardiovascular mortality
analysis and 49% of the weight in cardiovascular events analysis.
There was no strong evidence that cardiovascular events (fatal and
non-fatal combined) were reduced in people with normal blood
pressure (longest follow-up RR 0.71, 95% CI 0.42 to 1.20, 200
events, 2505 participants), but in hypertensives there was weak
evidence of benefit (longest follow-up RR 0.77, 95% CI 0.57 to
1.02, 192 events, 3407 participants). Maximising the available
data by pooling across normotensive and hypertensive groups and
using the data collected by some trials after the trial end date gave
a ’significant’ result (RR 0.77, 95% CI 0.63 to 0.95, P value <
0.01). This result was driven by the trial of residents in institutions
where salt reduction was achieved by changes in salt used in the
institution kitchens (Chang 2006). Excluding this trial from the
analysis gave an overall effect of RR 0.81 (95% CI 0.63 to 1.03)
for cardiovascular events at longest follow-up. Both TOHP I 1992
and TOHP II 1997 were carried out in overweight individuals
(average body mass index (BMI) in TOHP I 27.1, mean BMI in
TOHP II 30.9 in both intervention and control), so the effects of
dietary advice to reduce salt found in this trial may not be appli-
cable to non-overweight people.
Although no data were published on participant’s health-related
quality of life, in one trial among normotensives it was reported
that there were significant improvements in quality of life in the
intervention group (TOHP I 1992).
The interventions reduced urinary sodium excretion and indicated
that participants continued to comply with sodium restriction in
the long term, at least to some degree, although, as noted in a
previousCochrane review, the degree of sodium restriction is likely
to attenuate over time (Hooper 2004). End of trial systolic and
diastolic blood pressure were reduced by an average of 1 mmHg in
normotensives and by an average of 2 to 4mmHg in hypertensives.
Sustained long-term reductions of diastolic blood pressure of 1
mmHg and 4mmHg would be predicted to reduce cardiovascular
disease mortality by 5% and 20% respectively (MacMahon 1990).
Our point estimates among hypertensives are consistent with ef-
fects of this size, but have wide confidence intervals owing to the
relatively small number of events. Among normotensives our point
estimate of benefit is rather larger (about a 30% risk reduction
in cardiovascular events), which probably reflects the use of the
long-term follow-up data from the TOHP I and II trials These
provide the only relevant data but they may be biased by losses
to follow-up for non-fatal events and no data on blood pressure
or urinary sodium excretion were available to assess the extent to
which participants had maintained trial values (Cook 2007). The
systolic blood pressure reduction in the TOHP I and II trials was
between 1 mmHg and 2 mmHg, which would not be expected to
produce such a large reduction in cardiovascular events.
Findings from sensitivity analysis excluding cluster-randomised
trials are less precise, but overall are consistent with the main anal-
ysis.
Overall completeness and applicability of
evidence
A previous Cochrane review was limited by the lack of reported
events (17 deaths, 93 cardiovascular events) (Hooper 2004). In
this review, because of longer observational follow-up (up to 10 to
15 years) of three of the trials included in the previous Cochrane
review (TOHP I 1992; TOHP II 1997 (eight years); TONE 1998
(12.7 years)) and inclusion of one more recent randomised con-
trolled trial (RCT) (Chang 2006), we have gatheredmore evidence
on mortality and cardiovascular outcomes (approximately 7200
13Reduced dietary salt for the prevention of cardiovascular disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
participants, 753 deaths and 392 cardiovascular events). Never-
theless, the total amount of evidence on events remains limited.
The question arises of howmuchmore evidence would be required
to give a conclusive answer on the benefits of advice to reduce salt
intake. Assuming a 15% risk of suffering a cardiovascular event
over 10 years (consistent with mild hypertension at age 60 in a
man), a trial with 80% power and a significance level of 5% would
require randomisation of about 25,000 people to intervention and
control armswith follow-up for 10 years to detect a 10% reduction
in cardiovascular events. However, targeting a 20% reduction in
cardiovascular events - similar to the effects of antihypertensives
or statins in primary prevention of cardiovascular disease - and a
shorter follow-up of five years would require a more feasible trial
of 12,000 participants. The randomised evidence to support anti-
hypertensive drug treatment comprises over 120,000 participants
followed for about five years and provides conclusive evidence of
benefit. Despite over a decade of advocacy for salt reduction as a
major public health strategy, it is remarkable that an evidence base
a 10th of the size of the equivalent pharmacological database has
been produced. Doing better than this is considered impracticable
because of logistic, financial and ethical issues (He 2011).
More recently, the US Institute of Medicine, in its review of the
evidence on salt and health, has recommended further trials to
examine the effects of a range of sodium levels on the risk of car-
diovascular events, stroke and mortality among patients in con-
trolled environments, where randomised trials may be more feasi-
ble, and in natural experiments (Institute of Medicine 2013). In
response to this the TOHP I and II trial investigators reported
long-term observational findings from the control groups of these
trials, which did not show a J-shaped association but indicated that
urinary sodium excretion is linearly associated with cardiovascular
events, although only 10% of the participants had urinary sodium
excretions of below 2300mg/24 hours (Cook 2014), a little higher
than the level of 2000 mg/24 hours recommended by the World
Health Organization (WHO 2012). In contrast, an observational
cohort analysis was unable to demonstrate a clear linear relation-
ship between urinary sodium excretion and coronary heart dis-
ease events, although a weak interaction between urinary sodium
excretion and plasma N-terminal pro-B-type natriuretic peptide
on coronary heart disease events was reported (Joosten 2014). Re-
viewing these new studies, Whelton stated that “... the potential
for reverse causality, bias in assessment of sodium intake, absent
or insufficient adjustment for confounding variables, and random
error” all contribute to inconsistent findings (Whelton 2014).
Quality of the evidence
Although all included studies were RCTs, only two of the eight
included studies provided sufficient detail to be judged as hav-
ing adequate random sequence generation, allocation concealment
and outcome blinding. One cluster-randomised trial was analysed
as if it was individually randomised (Chang 2006). Nevertheless,
all trials provided evidence of baseline balance. Although lack of
blinding is unlikely to alter outcome assessment when outcomes
include mortality and cardiovascular events, failure to blind par-
ticipants may have led to a positive change in the lifestyle and
dietary behaviours of control participants, leading to a reduction
in the difference between groups.
Most trials appeared to be free from dietary changes in the in-
tervention and control groups, apart from dietary sodium. The
one major exception was the trial by Chang where sodium was
replaced by a high-potassium substitute (Chang 2006). Potassium
has beneficial effects onbloodpressure butmay have adverse effects
in individuals with renal disease (Cappuccio 2000). Two studies
in hypertensives allowed changes in antihypertensive medication
during the period of the trial (Morgan 1978; TONE 1998). In
both trials, lower levels of hypertensive medication in the inter-
vention group compared to control may have reduced the blood
pressure-lowering effect of reduced dietary sodium and therefore
offset mortality and cardiovascular morbidity benefits.
Potential biases in the review process
We searched comprehensively for randomised controlled trials of
dietary sodium reduction, with a duration of six months or more
and which reported mortality or cardiovascular events. We at-
tempted to contact all authors of included studies to verify events.
Nevertheless, we were unable to report all relevant outcomes for
all trials. The small number of included studies prevented us from
being able to assess the presence of small study or publication bias.
By incorporating data from the longest follow-up point, we sought
to maximise the number of deaths and cardiovascular events that
might be affected by alterations in dietary salt. However, in do-
ing so we may have introduced a source of bias as not all trials
conducted long-term follow-up. For three large studies (TOHP I
1992, TOHP II 1997 (eight years), TONE 1998 (12.7 years)),
the longest follow-up was considerably beyond the official end of
the trial and therefore can no longer be assumed to represent a
randomised comparison. It was unclear if the intervention groups
continued their low-salt diets and whether control groups were left
to continue with dietary advice or advised to reduce their salt. For
this reason we consider the trial end findings to be a more robust,
albeit less precise, source of evidence.
In common with previous systematic reviews of dietary interven-
tions, we observed marked heterogeneity across studies in terms
of their population, sample size and follow-up. Whilst we strat-
ified meta-analysis by differing sub-populations (normotensives
and hypertensives) and pooled studies using weighting based on
sample size, we did not account for the duration of follow-up. A
previous Cochrane review suggests that over time the sodium re-
duction achieved is greatly reduced, as is the effect on blood pres-
sure and therefore the effect on events is potentially diminished
(Hooper 2004). In a systematic review of trials of dietary salt re-
duction, sodium excretion was about half that in the two trials of
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over one-year duration compared with the other trials with a me-
dian duration of four to five weeks (He 2013a; He 2013b), indi-
cating that long-term blood pressure reductions would be smaller
with commensurate reductions in clinical benefit.
Agreements and disagreements with other
studies or reviews
Our finding of a lack of strong evidence of an effect of dietary
sodium reduction advice onmortality and cardiovascular events in
our 2011 Cochrane review was strongly contested on the grounds
that we failed to consider the totality of the epidemiological, ani-
mal and short-duration trials of blood pressure reduction, and that
if we had pooled across people with and without hypertension our
findings would have achieved statistical significance (He 2011).
The effects of dietary salt advice are greater in people with hy-
pertension (possibly because of greater adherence) and underlying
risks of cardiovascular disease are higher, which was our rationale
for providing separate analyses. Indeed, the ’significant’ effect that
He andMacGregor achieved becomes ’non-significant’ depending
on whether the odds ratio (0.78, 95% CI 0.61 to 0.99, P value =
0.045) or rate ratio (0.88, 95%CI 0.77 to 1.00, P value = 0.054) is
estimated, indicating the limitations of the available evidence and
the problem of basing decisions on arbitrary thresholds of statisti-
cal significance (Taylor 2011). Another Cochrane review examin-
ing the physiological effects of dietary salt reduction in a 167 trials
found a 1% decrease in blood pressure in normotensives, a 3.5%
decrease in hypertensives, a significant increase in plasma renin,
plasma aldosterone, plasma adrenaline and plasma noradrenaline,
a 2.5% increase in cholesterol and a 7% increase in triglyceride.
The authors concluded, “There were increases in some hormones
and lipids which could be harmful if persistent over time. How-
ever, the studies were not designed to measure long-term health
effects. Therefore we do not know if low-salt diets improve or
worsen health outcomes.” (Graudal 2011). In a further Cochrane
review, restricted to 34 trials of at least four weeks duration, there
was no strong evidence of these hormonal and lipid effects, sug-
gesting that they may not be long-term problems (He 2013a; He
2013b).
In light of the limited randomised evidence, non-randomised
observational evidence has been reviewed and meta-analysed. In
a review of prospective observational studies that examined the
relationship between dietary sodium and cardiovascular events
(Strarzzullo 2009), 13 cohort studies (177,025 participants) with
follow-up of 3 to 17 years were included. Higher salt intake was as-
sociatedwith a greater risk of stroke (pooled relative risk 1.23, 95%
CI 1.06 to 1.43, 5161 events) and cardiovascular events (pooled
relative risk 1.14, 95% CI 0.99 to 1.32, 5346 events). Total and
cardiovascular mortality were not reported. A more recent update
of this review reported inconclusive findings for all-cause mor-
tality and cardiovascular events, but did report an increased risk
of coronary mortality (pooled relative risk 1.32, 95% CI 1.13 to
1.53) and stroke events (pooled relative risk 1.24, 95% CI 1.08 to
1.43) in those with high salt intakes (Aburto 2013). The inherent
limitation of both of these reviews is the observational nature of
the evidence on clinical outcomes, i.e. the studies describe the life
course of persons who follow a self selected diet, unlike in ran-
domised trials where allocation is at random and not self selected.
People who choose a lower-salt diet are likely also to eat a diet
of fresh foods, lower in fats and refined carbohydrate, take more
exercise and be less likely to smoke, so that their lower levels of
deaths and disease may not relate to salt intake at all.
Dietary advice appears to be only modestly effective at reducing
salt intake and consequently has only small effects on blood pres-
sure, particularly in the general population. Alternative means of
reducing dietary salt intake include salt substitution, which may
be relatively easy to implement in institutional and workplace
kitchens as indicated in the one trial of an institutional kitchen in-
tervention in this review (Chang 2006). Experience in the United
Kingdom and elsewhere has demonstrated that voluntary regula-
tion, with the threat of government legislation, by the food indus-
try has resulted in reductions in dietary sodium intake, although
the effects have been small (a reduction from 9.5 g/day to 8.6 g/
day but remaining a long way from a target of 6 g/day (Cappuccio
2011; Millett 2012). Evidence from other countries suggests that
regulatory approaches are needed (Webster 2011), and are cost-
saving compared with dietary advice, which is not cost-effective
in Australian scenarios (Cobiac 2010). In a recent review of the
evidence, Whelton considered that “... a gradual decrease in the
addition of Na to food products represents the easiest ”lifestyle“
change for the general population and the interventionoptionwith
the greatest potential for success” (Whelton 2014). In most coun-
tries, establishing means of monitoring progress, both in terms of
population levels of dietary salt intake and blood pressure, will be
essential.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite collatingmore event data than previous systematic reviews
of randomised controlled trials, there is insufficient power to con-
firm clinically important effects of dietary advice and salt substitu-
tion on cardiovascular mortality in normotensive or hypertensive
populations. The methods of achieving salt reduction (advice and
salt substitution) in the trials included in our review, and other sys-
tematic reviews, were relatively modest in their impact on sodium
excretion and on blood pressure levels. They generally required
considerable efforts to implement and would not be expected to
have an effect on the burden of cardiovascular disease commensu-
rate with their costs. The challenge for clinical and public health
practice is to find more effective interventions for reducing salt
intake that are both practicable and inexpensive.
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Many countries have national authoritative recommendations, of-
ten sanctioned by government, which call for reduced dietary
sodium. In the UK, the National Institute of Health and Care
Excellence (NICE) has recently called for an acceleration of the re-
duction in salt intake of the general population from a maximum
intake of 6 g per day per adult by 2015 to 3 g by 2025 (NICE
2010).
Implications for research
Further long-term follow-up of existing trials (as done by Tri-
als of Hypertension Prevention (TOHP) I, TOHP II and Trial
of Nonpharmacologic Intervention in the Elderly (TONE)) may
contribute further events to allow assessment of the long-term ef-
fects of reduced dietary salt advice on mortality, cardiovascular
morbidity and hormonal and lipid outcomes, although the inten-
sive dietary advice interventions evaluated in trials over the last
three decades are of less relevance to current policy initiatives. Our
findings support the recent US Institute of Medicine recommen-
dation for further rigorous, large, long-term studies, capable of
demonstrating the cardiovascular benefit of dietary salt reduction
beyond reasonable doubt using a range of plausible interventions.
Such trials need to assess population level (e.g. workplace, institu-
tional, regulatory) interventions that might be more likely to lead
to sustained reductions in salt intake and which would provide
evidence relevant to current public health guidelines. It will also
be important to evaluate the effects of voluntary and regulatory
salt reduction by food industries (such as the UK’s reduction of
salt in processed foods) on dietary salt intake and blood pressure,
as these may hold greater opportunities for practicable and inex-
pensive means of reducing salt intake in the population at large.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chang 2006
Methods Cluster-RCT (5 kitchens)
Participants N randomised: 1981 (N = 768 intervention, 2 kitchens; N = 1213 control, 3 kitchens)
Baseline blood pressure: intervention: SBP mean 131.3 (SD 19.7), DBP mean 71.2
(SD 10.8); control: SBP mean 130.7 (SD 20.4), DBP mean 71.4 (SD 10.8)
Case mix: intervention: 40.2% hypertension; control: 40.4% hypertension
Age: mean 75.6 (SD 7.7), 74.8 (7.0), in kitchens 2 and 3 (intervention group) 74.8 (7.
3), 74.6 (6.7), 74.6 (6.1) in kitchens 1, 4 and 5 (control group) respectively
Cardiovascular diagnoses: none reported
Percentage male: 100%
Percentage white: not reported
Inclusion/exclusion criteria:
Inclusion: veterans registered in a retirement home in Northern Taiwan
Exclusion: bed-ridden veterans, high serum creatinine (i.e. >= 3.5 mg/dL)
Funder: Taiwan Salt Work, Tainan, Taiwan, ROC
Interventions Intervention
Total duration: average of 31 months
Salt reduction/advice component: ate food prepared by the cook of the kitchen to
which they were assigned, using salt containing 49% sodium chloride, 49% potassium
chloride and 2% other additives. The ’potassium enriched salt’ replaced the regular salt
in the selected kitchens in a gradual manner. It was mixed with regular salt in a 1:3 ratio
for the first week; it was then increased to 1:1 for the second week and 3:1 for the third
week. By the 4th week the cooks solely used the potassium-enriched salt
Other dietary component: other condiments and spices such as soy sauce and
monosodium glutamate were not limited because reasonably priced low-sodium soy
sauce and monosodium glutamate were not available at the time of the trial
Comparator
Dietary: ate food prepared by the cook of the kitchen to which they were assigned using
’regular salt’ containing 99.6% sodium chloride and 0.4% other additives at all times.
Other condiments and spices such as soy sauce and monosodium glutamate were not
limited because reasonably priced low-sodium soy sauce and monosodium glutamate
were not available at the time of the trial
Outcomes Deaths (all-cause and CVD); costs of CVD health care
Follow-up Average 31 months
Country and setting Taiwan - veterans’ retirement home
Notes Outcomes are not reported by kitchen so not possible to quantify the effect of clustering
The authors reported the number of deaths due to cardiovascular disease and elsewhere in
the table of number of deaths due to other heart problems. In themost current update we
included these deaths under cardiovascular mortality. Also, the authors included deaths
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Chang 2006 (Continued)
due to diabetes under deaths due to cardiovascular disease. We emailed the authors to
ask about this inclusion and they replied, “As to diabetes, we included it in CVD because
we knew locally at the time our coders coded death to be due to diabetes as long as
diabetes is related and diabetes occurred earlier. For example, if a person has diabetes
and stroke, the code would be diabetes. That is why we grouped diabetes in the CVD
category which can be viewed as the cardiometabolic death. A large proportion of dm
death is due to CVD”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The simplest randomisation method, i.e., drawing
lots, was used.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The veterans were told about the trial, but were
not told to which salt they were assigned.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not stated, however primary outcomes are clinical and un-
likely to be affected by outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk It appears that all subjects were followed up for the deaths
outcome. A consort diagram and reasons for losses to fol-
low-up for other outcomes are given. No sensitivity anal-
ysis or imputation was carried out to assess the impact of
missing data
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in the
results
Assessment of compliance? Low risk Subjects ate food that was prepared for them
Groups balanced at baseline? Low risk Quote: “The ages of persons in different kitchens were not
significantly [different] at entry (P=0.24). The results also
indicated that weight, height, body mass index, blood pres-
sure, and electrolytes for a subsamples of persons in the ex-
perimental and control groups were not significantly differ-
ent at baseline. Persons in [the experimental kitchens] had
slightly longer follow-up times than did their counterparts
[in the control kitchens]; however, the difference did not
reach statistical significance (P=0.11).”
Intention-to-treat analysis? Low risk Not specifically reported, but on the basis of the consort
diagram, subjects did appear to be analysed according to
the groups to which they were originally allocated
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Chang 2006 (Continued)
Free from follow-up bias? Low risk The dietary intervention was applied over the period of
event outcome follow-up
CSSS 2007
Methods RCT
Participants N randomised: 608; intervention: 302, control: 306
Baseline blood pressure: intervention: 159/93 (25/14), control: 159/93 (26/14)
Case mix: mixed
Age: mean 60 years; intervention: 59 (10), control: 61 (9.7)
Cardiovascular diagnoses: history of vascular diseases, intervention: 62%, control: 66%
Percentage male: 44% male; intervention: 48%, control: 42%
Percentage white: not reported
Inclusion/exclusion criteria:
Inclusion: individuals with a high risk of future vascular disease based on a doctor’s
diagnosis of any of the following: coronary, cerebral or peripheral vascular disease, dia-
betes and aged 55 years or older or a systolic blood pressure of 160 mmHg or higher.
In addition, all participants were required to have an estimated daily sodium intake of
260 mmol/day or more and an expectation that at least half of the dietary salt could be
replaced with the study salt or salt substitute. Participants were required to have no es-
tablished clear indication for, or contra-indication to, the use of the study salt substitute,
such as use of a potassium-sparing medication or significant renal impairment
Exclusion: any individual with a blood test result considered to be possibly abnormal.
Any patient with a family member who had a contra-indication to the salt substitute
Funding: the George Institute for International Health (Australia), the Clinical Trials
Research Unit (New Zealand), the Capital Medical Science Development Fund (China)
and the National Health and Medical Research Council of Australia
Interventions Salt reduction/advice component: salt substitute. The salt substitute was 65% sodium
chloride, 25% potassium chloride and 10% magnesium sulphate
Comparison:
100% sodium chloride
Outcomes Death, BP, urinary sodium excretion
Follow-up 1, 2, 3, 6, 9 and 12 months after randomisation
Country and setting China; 39 sites in 6 regional co-ordinating centres
Notes 2 lost to follow-up in the control group; 6 lost to follow-up and 1 withdrew in the
intervention group. Do not report enough data for us to calculate standard deviations
for MD in SBP and DBP
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation done using a central, computerised randomisa-
tion service accessed by centre physicians via the study website
with a back-up phone and fax service. The service was main-
tained by the Clinical Trials Research Unit at the University of
Auckland, New Zealand
Allocation concealment (selection bias) Low risk The randomisation service provided a unique number for each
individual corresponding to a treatment pack held at the centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment allocation was blinded to study investigators, partic-
ipants and centre physicians until the study database was un-
locked. Randomised treatment was delivered in 1 kg bags identi-
cal except for a 3-digit code corresponding to the randomisation
number, with up to 3 kg a month salt substitute/salt available to
each randomised participant to cover all cooking, pickling and
other uses within the household. Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treatment allocation was blinded to study investigators and cen-
tre physicians until the study database was unlocked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data not provided for hypertensives (61%) or those with dia-
betes (16% to 19%); values for urinary sodium excretion and
BP not given
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Assessment of compliance? Low risk Participants that were randomised reported very good adherence
to study salt substitute/salt with 99% of individuals stating that
they used study salt substitute/salt for all or nearly all of their day-
to-day food preparation with no difference between randomised
groups (P value = 0.40)
Groups balanced at baseline? Low risk Appeared similar at baseline
Intention-to-treat analysis? Unclear risk No (5% missing data so no imputations were made for missing
data). Final follow-up visit attended by 96% of randomised par-
ticipants and overall 98% of all post-randomisation visits com-
pleted as scheduled
Free from follow-up bias? Unclear risk Follow-up very high, with no evidence of differences between
groups
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Methods Individual RCT
Participants N randomised: 392 (N = 196 intervention, N = 196 control)
Baseline blood pressure: intervention: SBP mean 124.0 (SD NR), DBP mean 82.6
(SD NR); control: mean SBP 123.9 (SD NR), DBP mean 83.0 (SD NR)
Case mix: normotensives
Age: intervention: mean 39.0 (SD NR); control: mean 38.5 (SD NR)
Cardiovascular diagnoses: none
Percentage male: 65%
Percentage white: 82%
Inclusion/exclusion criteria:
Inclusion: men and women aged 25 to 49 years; DBP 78 to 89 mmHg
Exclusion: use of antihypertensive medication, evidence of CVD, BMI >= 0.0035 kg/
cm², dietary requirements incompatible with any of the interventions, drank 21 or
more alcoholic drinks per week, pregnant women, unable to comply with the protocol
requirements
Interventions Intervention
Total duration: 36 months
Salt reduction/advice component: dietary counselling (in groups) aimed at sodium
restriction. The groups met once a week for the first 10 weeks, once every 2 weeks for
the next 4 weeks, and then once every month for the rest of treatment and follow-up.
The group goal was a 50% reduction (<= 70 mmol) in mean urine sodium. Personnel
delivering the interventions were trained and experienced in effecting behaviour change.
Counselling included a mixture of didactic presentations and demonstrations, token
incentives, telephone calls and newsletters
Other dietary component: none stated
Comparator
Dietary: no dietary counselling
Outcomes BP, urinary Na excretion, deaths (all-cause)
Follow-up 36 months
Country and setting USA; 4 clinics
Notes - Factorial design (calorie restriction and potassium supplementation not reported here
- 841 participants in total in study)
- No difference in proportion of individuals in each group who began hypertensive
medication (8.4% intervention versus 9.0% control) over 36 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation procedure involved a fixed assign-
ment ratio design that provided for equal numbers of assign-
ments within clinic and weight strata in blocks (randomly or-
dered) of size 3, 6, or 9 for the normal weight stratum and of
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size 5 to 10 for the high-weight stratum.”
“Randomisations were performed on demand at the individual
clinic centers (using a pseudo-random number generator pro-
vided with the S/23 BASIC language) with schedules and soft-
ware for issuing assignments generated by the DCC.”
Allocation concealment (selection bias) Low risk Quote: “Randomisations were performed on demand at the in-
dividual clinic centers (using a pseudo-random number genera-
tor provided with the S/23 BASIC language) with schedules and
software for issuing assignments generated by the DCC. Clinic
personnel had to key all [Baseline 1 and Baseline 2 visit] data
and those contained on part I of the [Baseline 3 visit] data before
an assignment could be obtained (via the S/23)”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “In order to reduce observer bias, data collection and
treatment visits for dietary counselling were not held in the same
week for a given participant, and data collection (i.e., interviews,
measurements, food record review, and the like) were carried
out by personnel not involved in treatment.” “Participants were
asked not to [...] divulge or discuss their dietary counselling with
data collection personnel.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated, but as primary outcomes are clinical they are unlikely
to be affected by outcome assessor’s risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers in each group at each assessment time point were re-
ported. The only reasons given for losses to follow-up were non-
attendance at follow-up visits or death. No sensitivity analysis
or imputation undertaken to assess the impact of loss to follow-
up
Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results
Assessment of compliance? Low risk Quote: “Attendance during the first 12 counselling sessions
ranged from a high of 86.5% for the Na treatment group in
the sodium-calorie component at session 1 to a low of 46.8%
for that same treatment group at session 12. Attendance for all
counselling groups declined with time (test for linear decline,
P<.001). Generally, attendance over the 12 sessions was better
for the two treatment groups involving calorie restriction [...]
than for the other two dietary treatment groups [including the
sodium reduction group].”
“For the purposes of this article, we use progress toward or at-
tainment of dietary treatment goals as indices of compliance. [..
.] As a first level of exploratory analysis, univariate and multiple
linear regressions were conducted comparing 34 baseline and
process variables with urine sodium excretion [....] as [one of
the] dependent variables. [ ....] In the second level of analysis,
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compliance was defined in terms of achieving treatment goals.
For the sodium reduction groups, compliance was defined as
having a 24-hr urine excretion of less than or equal to 70mEq.”
Groups balanced at baseline? Low risk Quote: “Except for sex there were nomarked baseline differences
among the treatment groups.”
Intention-to-treat analysis? Low risk Quote: “All results are presented by original treatment assign-
ment.”
Free from follow-up bias? Low risk Duration of intervention same as follow-up time for event out-
comes
Kwok 2012
Methods Cluster-RCT
Participants N randomised: 429 (14 hostels); intervention: 204 (6 hostels), control: 225 (8 hostels)
Baseline blood pressure: intervention: SBP 139.2 (16.6), DBP 78.9 (9.3); control: SBP
141.0 (18.5), DBP 78.4 (8.7)
Case mix: intervention: 55.4%, control: 64.4%
Age: 75+, average age intervention: 83.1 (5.7), control: 83.3 (5.5)
Cardiovascular diagnoses: none
Percent male: intervention: 22.1%, control: 9.3%
Percent white: not stated
Inclusion/exclusion criteria:
Inclusion: men and women 75 years and older in old age hostels run by 2 non-govern-
ment organisations
Exclusion: tube-fed residents, individuals on a special diet due to chronic renal failure
Funding: Tung Wah group and private donations
Interventions Total duration: 33 months
Salt reduction/advice component:
1) Research dietician gave a 1-hour talk to residents and staff on the prevention of
dementia and promoted the ’brain preservation diet’ with the following targets including
avoidance of salty foods
2) Trained dietician conducted dietary support groups to reinforce the brain preservation
diet (group size ranged from 10 to 15 subjects), totalling 20 times in the first year, each
group session lasting 45 minutes. In the subsequent 21 months, the frequency of dietary
groups was reduced to once in 6 weeks to reinforce the intervention
3) The dietician also liaised closely with the hostel staffs and kitchen staff on the hostel
menu and cooking methods. Instead of using salt or other salty seasoning like fermented
tofu and oyster sauce, they suggested using peppers, ginger, onion, spring onion, garlic,
coriander and Chinese 5 spices powder. The hostel staff also helped to promote the ’brain
preservation diet’ in their homes
Comparator
1) Research dietician gave a 1-hour talk to residents and staff on the prevention of
dementia and promoted the ’brain preservation diet’ with the following targets including
avoidance of salty foods
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2) In the control hostels, the dietician gave advice on menus at the beginning of the trial
only
Outcomes Mortality, BP, urinary sodium excretion, health-related quality of life
Follow-up 12 months, 24 months, 33 months
Country and setting Hong Kong: 14 old age hostels
Notes Did not provide information on BP and health-related quality of life; only said that there
were no significant differences at 33 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated; “randomly assigned”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible for patients and caregivers to be blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not possible for outcome assessors to be blinded, however as
primary outcomes all clinical, unlikely to be affected by risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Appeared to report on all outcomes, although did not give data
for some of the outcomes, only stating that there were no dif-
ferences
Assessment of compliance? High risk Stated that “The dietary intervention was not successful in re-
ducing salt intake. Although salty foods in the menu of the in-
tervention homes were reduced significantly, the residents had
the option of adding salty flavouring, for example, soya sauce to
their foods.”
Groups balanced at baseline? Unclear risk More males in the treatment group, slightly higher BP in the
control group
Intention-to-treat analysis? Low risk Done
Free from follow-up bias? Low risk Yes
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Methods Individual RCT
Participants N randomised: 4-arm trial. 2 arms were of drug treatments and not considered here. The
dietary sodium restriction arm and control arm are used here. 67 (N = 34 intervention,
N = 33 control). Morgan 1980 reports on a longer follow-up and gives 42 allocated to
control and 33 to intervention arms
Baseline blood pressure: intervention: SBPmean 160 (SD23),DBP97 (SD8); control:
SBP mean 165 (SD 17), DBP mean 97 (SD 8)
Case mix: untreated hypertensives
Age: intervention: mean 57.1 (SD NR); control: mean 58.6 (SD NR)
Cardiovascular diagnoses: borderline hypertensives (DBP 95 to 109 mmHg) and hy-
pertensives (DBP 110+ mmHg)
Percentage male: 100%
Percentage white: not reported
Inclusion/exclusion criteria:
Inclusion: males with borderline hypertension on admission to hospital or outpatient
visit
Exclusion: malignant disease, severe psychiatric disturbances, severe physical incapacity
or a disease likely to be fatal in the next 2 years, serum-creatinine levels > 0.18 mmol/l,
abnormal liver function tests, in cardiac failure or on diuretic therapy
Funding: Australian Department of Veterans’ Affairs, the Australian National Heart
Foundation, Merck, Sharp & Dohme (Aust), Pty Ltd and ICI Australia Ltd
Interventions Intervention
Total duration: 24 months
Salt reduction/advice component: patients were instructed to reduce their sodium
chloride intake and were given a diet that should have reduced their sodium intake to 70
to 100 mmol/day. The advice about diet was repeated at 6 months. No details on who
gave advice
Other dietary component: at each 6-month review visit, if serum potassium levels < 3.
4 mmol/L, potassium supplements were given
Comparator
No treatment, reviewed at 6 months (as intervention)
Other: not given any treatment, but reviewed at 6-monthly intervals and if DBP rose
above 115 mmHg treatment was started
Outcomes Deaths (all-cause and CVD); BP; urinary Na excretion
Follow-up BP at 24 months; clinical outcomes at 24 months (end of trial) and at extra follow-up
to 70 months
Country and setting Australia - single hospital
Notes Cardiovascular morbidity and mortality data taken from review of Morgan 1978 and
Morgan 1980
Taking antihypertensive medication (at 6 months): intervention 4/10 versus control 9/
10 (RR 0.44, 95% CI 0.20 to 0.98)
Longer-term follow-up reported in Med J Australia 1980. Note that denominators for
long-term findings are taken from this report
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “[patients] were randomly divided into 4 subgroups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not reported but as primary outcomes clinical unlikely to be
affected by risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Information regarding life or death was not known for
two patients, who were excluded from the study. All patients
included in the study were seen at the initial visit, and at a
subsequent six-month visit. Patients who did not report back on
at least one occasion have not been analysed. Five patients died
in the first six months; these have been included in the analysis.
There were no other known deaths in this time interval in the
patients who did not report back. More than 90% of initially
allocated patients reported back at the end of the first six-month
period.”
The only reason given for losses to follow-up was patients not
reporting back.No sensitivity analysis or imputation undertaken
to assess the impact of loss to follow-up
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported at some
point in the results
Assessment of compliance? Low risk Urinary sodium is measured and although it is not specifically
stated that this was used to assess compliance, it is implied.
Quote: “Patients in the dietary therapy group who continued to
have a high sodium excretion were advised about their diet.”
Groups balanced at baseline? Low risk Quote: “At the start of the study the groups were similar in age,
weight, height, pulse-rate, and serum electrolytes, urea, creati-
nine, uric acid, glucose, and cholesterol. The initial systolic and
diastolic blood-pressures, supine and standing, did not differ
among the groups”.
Intention-to-treat analysis? Low risk Although the term ITT is not used by the authors it appears that
groups were analysed as randomised
Quote: “[Morgan et al’s (1980)] report does not exclude patients
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who changed therapy or ceased therapy. It evaluates the proposi-
tion: ’Did the decision to implement therapy alter the mortality
rate in patients with mild hypertension’?”
Free from follow-up bias? High risk Longest event follow-up for mortality was 71 months but last
stated diet advice stated as 6 months. No urinary sodium excre-
tion data available at longest follow-up
TOHP I 1992
Methods Individual RCT
Participants N randomised: 744 (intervention: 327 and control: 417)
Baseline blood pressure: intervention: SBPmean 124.8 (SD 8.5), DBP mean 83.7 (SD
2.7); control: SBP mean 125.1 (SD 8.1), DBP mean 83.9 (SD 2.8)
Case mix: normotensives
Age: intervention: 43.4 (SD 6.6); control: 42.6 (SD 6.5)
Cardiovascular diagnoses: none
Percentage male: 71.4%
Percentage white: 77.2%
Inclusion/exclusion criteria:
Inclusion: aged 30 to 54: mean DBP 80 to 89 mmHg without antihypertensive med-
ication; ability to complete and return a satisfactory 24-hour urine collection and food
frequency questionnaire
Exclusion: long list of exclusion criteria, generally designed to eliminate patients with:
evidence of medically diagnosed hypertension (DBP >= 90 mmHg or use of BP medi-
cations within 2 months of first evaluation), cardiovascular or other life-threatening or
disabling diseases, gross obesity (BMI > 36.14), a contraindication to any of the phase
I interventions, or might have difficulty complying with the treatment or follow-up re-
quirements of the trial
Interventions Intervention
Total duration: 18 months
Salt reduction/advice component: dietary and behavioural counselling on how to iden-
tify sodium in the diet, self monitor intake and select or prepare low-sodium foods and
condiments suited to personal preferences. Individual and weekly group counselling ses-
sions were provided during the first 3 months, with additional less frequent counselling
and support for the remainder of follow-up. Sessions were provided by nutritionists, psy-
chologists, or other experienced counsellors. The objective was to reduce urinary sodium
excretion in the intervention group to 80 mmol/24 hours
Comparator
Dietary: usual diet. General guidelines for healthy eating were given
Outcomes All-cause mortality, cardiovascular morbidity, BP and 24-hour urinary sodium excretion
Follow-up 11.5 years (”additional ~10 yrs observational follow up“)
Country and setting USA; 6 clinics
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Notes TOHP I design included allocation to other interventions (weight loss, stress manage-
ment and supplements, e.g. fish oil)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Quote: ”the clinic notified the coordinating center [of partici-
pant eligibility] by telephone and obtained a randomisation as-
signment. Clinics were also provided with sealed envelopes con-
taining randomization assignments for use when telephone con-
tact with the coordinating center was not possible.“
”adherence to the appropriate assignment sequence was moni-
tored by the coordinating center.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”To minimize bias, [BP] observers were blinded to treat-
ment allocation. Persons certified to measure BP were not in-
volved with intervention aspects of the trial, nor were they al-
lowed access to data that would reveal group assignment. When
possible, separate facilities or entrances were used for data col-
lection visits as compared to intervention visits.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”In order to reduce observer bias, data collectors were
blinded to the treatment assignment of the participants.“ Pri-
mary outcomes all clinical and are unlikely to be affected by risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”In the analyses shown, participants with no follow-up
visits [...] were assigned a zero value for BP change (“intention-
to-treat” analysis). These results did not differ appreciably from
those in which missing BP values were treated as missing at
random and excluded from the analysis.“
”The effect of missing urinary sodium excretion data at follow-
up on estimates of the absolute change from baseline was as-
sessed by assuming no change (the baseline sodium excretion
value was imputed). To reduce the likelihood that estimates of
treatment group differences were influenced by the inclusion of
incomplete samples, mean differences in urinary sodium excre-
tion at 6, 12, and 18 months were recalculated excluding urine
values associated with a volume less than 500g or, in separate
analyses, associated with creatinine or creatinine per kilogram of
body weight less than 85% of the within-person average. Mean
treatment group differences with these exclusions were very sim-
ilar to each other and to those calculated when all samples were
included.“
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Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results
Assessment of compliance? Low risk Quote: ”Twenty-four-hour urine samples were used to monitor
sodium reduction“ [....] In addition, food frequency question-
naire and 24-hour dietary recall estimates of sodium intake were
obtained from all life-style participants.”
“Compliance with the three life-style interventions was satisfac-
tory, both in terms of attendance at counselling sessions and in
reaching specific goals. [...] The group difference [in urinary Na
excretion] was maximal (58mmol/24h) at 6 months, [...] the
mean reduction [in urinary Na excretion] was well-maintained.
”
“The Data Coordinating Center provided guidelines for esti-
mating adherence to the counselling goal of 60mmol sodium
/24hr from the average sodium excretion in two 8-hour urine
samples collected at least 2 days apart.”
Groups balanced at baseline? Low risk Quote: “Baseline characteristics were evenly distributed, except
for age, which was higher in the sodium reduction intervention
group”
Intention-to-treat analysis? Low risk Quote: “In a sensitivity analysis using logistic regression we per-
formed an intention to treat analysis treating non-responders as
non-events. Because mortality follow-up was virtually complete,
we included all randomised participants in analyses of mortality
alone in a full intention to treat analysis.”
Free from follow-up bias? High risk Longest event follow-up for mortality and cardiovascular mor-
bidity was approximately 11.5 years but last stated diet advice
stated as 18 months. No urinary sodium excretion data available
at longest follow-up
TOHP II 1997
Methods Individual RCT
Participants N randomised: 2382 (intervention: 1191; control: 1191)
Baseline blood pressure: intervention: mean SBP 127.5 (SD 6.6), DBP mean 86.0 (SD
1.9); control: SBP mean 127.4 (SD 6.2), DBP SD 85.9 (SD 1.9)
Case mix: normotensives
Age: intervention: mean 43.9 (SD 6.2); control: mean 43.3 (SD 6.1)
Cardiovascular diagnoses: none
Percentage male: 65.7%
Percentage white: 79.3%
Inclusion/exclusion criteria:
Inclusion: 30 to 54-year old adults with no evidence of medically diagnosed hyperten-
sion, who were moderately overweight (men: between 26.1 and 37.4 kg/m²; women:
between 24.4 and 37.4 kg/m²), and had average DBP between 83 to 89 mmHg, and
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a SBP < 140 mmHg. Participants also had to demonstrate compliance with the more
difficult data collection tasks
Exclusion: evidence of current hypertension. History of CVD, diabetes mellitus, ma-
lignancy other than non-melanoma skin cancer during the past 5 years, or any other
serious life-threatening illness that requires regular medical treatment. Current use of
prescription medications that affect BP, as well as non-prescription diuretics. Serum cre-
atinine level >= 1.7 mg/dL for men or 1.5 mg/dL for women, or casual serum glucose
>= 200mg/dL. Current alcohol intake > 21 drinks/week. Pregnancy, or intent to become
pregnant during the study. Plans to move or inability to co-operate
Interventions Intervention
Total duration: 36 months
Salt reduction/advice component: individual and weekly group counselling sessions
were provided initially followed by additional less intensive counselling and support for
the remainder of follow-up. Mini-modules to reinforce the content of the counselling
sessionwere offered in the later years of the intervention. The content of sessions included
sodium information, self management and social support components. Sessions were
provided by registered dieticians mainly, plus a few psychologists, or other experienced
counsellors. The objective was to reduce urinary sodium excretion in the intervention
group to 80 mmol/24 hours
Other: the salt reduction intervention was combined with a weight loss intervention or
alone
Comparator
Dietary: no advice
Other: usual care or weight loss intervention alone
Outcomes All-cause mortality, cardiovascular morbidity (a composite of myocardial infarction,
stroke, coronary revascularisation or cardiovascular death), BP, urinary excretion
Follow-up 36 months
Country and setting USA; 9 clinics
Notes This study had a 2 x 2 factorial design in which the groups were: weight loss alone,
sodium reduction alone, a combination of weight loss and sodium reduction, and a usual
care group. The long-term effects of the sodium reduction intervention were analysed
by grouping data for the 2 sodium reduction interventions (alone or with weight loss)
and for the 2 non-sodium reduction groups (usual care and weight loss alone)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Quote: “The clinic then notified the coordinating center [of par-
ticipant eligibility] by telephone and obtained a randomisation
assignment. In those cases where random assignment was not
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done by phone, clinics also were provided with sealed random-
ization envelopes for use when contact with the coordinating
center was not possible.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “With respect to the determination of categorical end
points, in order to minimize bias in the ascertainment of hyper-
tension, an Endpoints Subcommittee conducts a blind review
of study forms, and as necessary, the medical records of partic-
ipants who are considered to have had hypertensive events. Po-
tential hypertensive end points identified are either confirmed
or refuted by the subcommittee.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[Data collectors] were masked to participants’ interven-
tion assignments.” Primary outcomes all clinical and are unlikely
to be affected by risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “For those with BP measurements but without urinary
sodium excretion data at the corresponding follow-up visit, a 0
change in urinary sodium excretion was imputed in a secondary
analysis.”
“For the small number of participants with no useable BP read-
ings after randomisation (n=99, of whom57%were treated early
with BP medications by their physicians), measures from a ran-
domly selected participant in the usual care group were imputed
under the assumption that having little or no exposure to the
intervention programs would produce similar results to that of
the usual care group.”
Selective reporting (reporting bias) Low risk All outcomes described in methods are reported in results
Assessment of compliance? Low risk Quote: “Intervention attendance also is collected for partici-
pants within each of the active intervention groups. The dietary
data are collected on random samples of equal numbers of par-
ticipants across the treatment groups. The 24-hour urine spec-
imens for sodium, potassium and creatinine measurements are
collected from all participants at 18 and 36 months. An addi-
tional 24-hour urine specimen, collected on a 25% sample of
trial participants at 6 months, was added to more fully assess
sodium intakes at this time as compared to baseline levels.”
“Urinary sodium excretion and weight change are collected as
intermediate end points for all participants. These intermediate
end points were selected to evaluate compliance to specific in-
terventions”
Groups balanced at baseline? Low risk Quote: “Baseline characteristics were evenly distributed, except
for age, which was higher in the sodium reduction intervention
group”
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Intention-to-treat analysis? Low risk Quote: “In a sensitivity analysis using logistic regression we per-
formed an intention to treat analysis treating non-responders as
non-events. Because mortality follow-up was virtually complete,
we included all randomised participants in analyses of mortality
alone in a full intention to treat analysis.”
Free from follow-up bias? Unclear risk Longest event follow-up for mortality and cardiovascular mor-
bidity was approximately 8 years but last stated diet advice stated
as 36 months. No urinary sodium excretion data available at
longest follow-up
TONE 1998
Methods Individual RCT
Participants N randomised: 681 (N = 340 intervention, N = 341 control) - part of a factorial design
study
Baseline blood pressure: SBP 128.0 (9.4), DBP 71.3 (7.3) mmHg
Case mix: treated hypertensives
Age: 65.8 (SD 4.6)
Cardiovascular diagnoses: none
Percentage male: 53%
Percentage white: 76%
Inclusion/exclusion criteria:
Inclusion: healthy, aged 60 to 80 years, SBP < 145 mmHg and DBP < 85 mmHg while
taking a single antihypertensive medication or a single combination regimen consist-
ing of a diuretic agent and a non-diuretic agent. Individuals taking 2 antihypertensive
medications were also eligible if they were successfully weaned off one of them during
the screening phase. Independence in activities of daily living. Capacity to alter diet and
physical activity in accordance with the requirements of any TONE intervention
Exclusion: diagnosis or treatment of cancer within the last 5 years; treatment with di-
uretics, ACE inhibitors, or digitalis for CHF or unknown reason; drug therapy with
nitrates, beta-blockers or calcium channel blockers for CHD or reason other than hyper-
tension; MI or stroke within 6 months; “active” CHD (e.g. angina pectoris); CHF; atrial
fibrillation; second- or third-degree heart block without permanent pacemaker; drug
therapy for ventricular arrhythmias; self report of heart valve replacement; clinically im-
portant valvular heart disease; insulin-dependent diabetes mellitus; severe hypertension;
current or recent (within 6 months) drug therapy for asthma or chronic obstructive lung
disease; use of corticosteroid therapy for > 1 month; serious mental or physical illness;
unexplained or involuntary weight loss (>= 4.5 kg) during the previous year; BMI < 21
in men or women, or > 33 in men or > 37 in women; serum creatinine > 2 mg/dL; non-
fasting blood glucose level of > 260 mg/dL; hyperkalaemia (> 5.5mmol/L); anaemia (Hb
level < 110 g/L); > 14 alcoholic drinks per week (assessed by self report); severe visual or
hearing impairment; other reason making it difficult for the participant to comply fully
with any part of the study protocol
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TONE 1998 (Continued)
Interventions Intervention
Total duration: 4-month “intensive” phase, plus 3-month “extended” phase, and then
a maintenance phase (duration of this phase is unclear)
Salt reduction/advice component: individual and group sessionswith an interventionist
(typically a registered dietician) who provided information using both centrally and
locally preparedmaterials, motivated participants to make and sustain long-term lifestyle
changes, and frequently monitored progress of groups and individuals. Individualised
feedback was provided. Participants learned about sources of sodium, in particular those
foods with a high salt content, and they learned about possible alternatives. They also
learned how to adapt the recommendations for a low-salt diet to their own lifestyle. The
goal of this intervention for the group was to achieve and maintain a 24-hour dietary
sodium intake of 80 mmol (1800 mg) or less (as measured by 24-hour urine collection)
Other: attempt to withdraw hypertensive therapy began 3 months post-randomisation
Comparator
Dietary: in order to enhance retention of control participants, meetings were held on a
regular basis with speakers on subjects unrelated to BP, CVD or nutrition
Other: drug withdrawal began at a comparable time to the intervention group
Outcomes Mortality (all-cause and cardiovascular), cardiovascular morbidity (a composite of my-
ocardial infarction, stroke, coronary artery bypass graft (CABG)), BP, urinary sodium
Follow-up 30 months
Country and setting USA; 4 clinical academic centres
Notes Unpublished all-cause mortality data at 12.7 years obtained from authors
No data specifically reported on number of individuals who stopped antihypertensive
medication in 2 groups
Multifactorial design. Only used sodium reduction without weight loss. Used in both
overweight and non-overweight groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Overweight participants were randomly assigned, in a
2x2 factorial design [...] Nonoverweight participants were ran-
domly assigned [...]”
“We used a variable block length randomization algorithm.”
(from investigators)
Allocation concealment (selection bias) Low risk Quote: “Assignments were made via computers at the clinic
sites, after eligibility criteria were confirmed. The sequences
were concealed from clinic staff?only known to statisticians at
the coordinating center.” (from investigators)
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TONE 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “To facilitatemasking of the data collectors, intervention
visits were conducted at separate times and places from the data
collection visits.”
“An end point committee, masked to intervention assignment,
made final decisions concerning the end point status of each
participant.”
“Outcome informationwas obtained by staffmembers whowere
blind to the participants’ intervention assignment, at different
times and different locations from those used for the interven-
tion visits. Participants were instructed not to reveal their inter-
vention assignment to the data collection staff.”
“Intervention staff members were masked with respect to the
participants’ BP and drug withdrawal status.”
“When questioned at the final follow-up visit, the data collectors
guessed the correct treatment assignment in 31% of the obese
participants (comparedwith an expected rate of 25%on the basis
of chance) and in 45% of the nonobese participants (compared
with and expected rate of 50% on the basis of chance).”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary outcomes all clinical and are unlikely to be affected by
risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk The only reason given for losses to follow-up was non-atten-
dance at follow-up visits. No sensitivity analysis or imputation
undertaken to assess the impact of loss to follow-up
Selective reporting (reporting bias) Unclear risk The authors report that data were collected via psychological
questionnaires at randomisation and a number of the follow-up
visits, but none of the data from these appear to be reported,
unless they are in a separate publication
Assessment of compliance? Low risk Quote: “Monitoring adherence (Reduced sodium life-style): At-
tendance; urinary data; food and behaviour records; adherence-
related incentives. Monitoring adherence (Usual (control) life-
style): Attendance.”
Groups balanced at baseline? Low risk Quote: “There was no evidence of a substantial imbalance be-
tween the reduced sodium and UL [usual lifestyle] groups [at
baseline]”
Intention-to-treat analysis? Low risk Quote: “Analyses were conducted on an intention-to-treat basis.
”
Free from follow-up bias? High risk Mortality outcome provided by authors at 12.7 years average
follow-up. No urinary sodium excretion data available at longest
follow-up
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ACE: angiotensin-converting enzyme
BMI: body mass index
BP: blood pressure
CHF: coronary heart failure
CHD: coronary heart disease
CSSS: China Salt Substitute Study
CVD: cardiovascular disease
DBP: diastolic blood pressure
Hb: haemoglobin
HPT: Hypertension Prevention Trial
ITT: intention-to-treat
MD: mean difference
MI: myocardial infarction
Na: sodium
NR: not reported
RCT: randomised controlled trial
ROC: Republic of China
RR: risk ratio
SBP: systolic blood pressure
SD: standard deviation
TOHP: Trials of Hypertension Prevention
TONE: Trial of Nonpharmacologic Intervention in the Elderly
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bentley 2006 Inadequate follow-up duration
Knuist 1998 Pregnant women
Koopman 1997 No appropriate outcomes
Licata 2003 Not dietary salt reduction intervention
Tobari 2010 No cardiovascular events
van der Post 1997 Pregnant women
Velloso 1991 Inadequate follow-up duration
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Characteristics of ongoing studies [ordered by study ID]
Aung 2012
Trial name or title RESIP-CVD Study
Methods Cluster-randomised trial
Participants High CVD risk patients stratified by the Framingham general CVD risk scoring system (> 15%)
Interventions Education regarding salt content in foods, subsequent cooking classes
Outcomes BP, CVD events, CVD mortality
Starting date Not stated
Contact information -
Notes -
BP: blood pressure
CVD: cardiovascular disease
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D A T A A N D A N A L Y S E S
Comparison 1. Reduced salt versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality at end of trial 7 6603 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.83, 1.10]
1.1 Normotensive 3 3518 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.40, 1.12]
1.2 Hypertensive 4 3085 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.86, 1.15]
2 All-cause mortality at longest
follow-up
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Normotensive 3 3518 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.58, 1.40]
2.2 Hypertensive 5 3680 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.87, 1.14]
3 Cardiovascular mortality at end
of trial
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Hypertensive 3 2656 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.45, 1.01]
4 Cardiovascular events at end of
trial
4 3397 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.57, 1.01]
4.1 Hypertensives 4 3397 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.57, 1.01]
5 Cardiovascular disease events at
longest follow-up
6 5912 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.63, 0.95]
5.1 Normotensive 2 2505 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.42, 1.20]
5.2 Hypertensive 4 3407 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.57, 1.02]
6 Systolic blood pressure at end of
trial
6 3362 Mean Difference (IV, Random, 95% CI) -1.79 [-3.23, -0.36]
6.1 Normotensive 3 2079 Mean Difference (IV, Random, 95% CI) -1.15 [-2.32, 0.02]
6.2 Hypertensive 3 1283 Mean Difference (IV, Random, 95% CI) -4.14 [-5.84, -2.43]
7 Diastolic blood pressure at end
of trial
5 2754 Mean Difference (IV, Random, 95% CI) -1.17 [-2.08, -0.26]
7.1 Normotensive 3 2079 Mean Difference (IV, Random, 95% CI) -0.80 [-1.37, -0.23]
7.2 Hypertensive 2 675 Mean Difference (IV, Random, 95% CI) -3.74 [-8.41, 0.93]
8 Urinary sodium excretion at end
of trial
6 3047 Mean Difference (IV, Random, 95% CI) -27.21 [-49.85, -4.
57]
8.1 Normotensive 3 1812 Mean Difference (IV, Random, 95% CI) -34.19 [-49.61, -18.
78]
8.2 Hypertensive 3 1235 Mean Difference (IV, Random, 95% CI) -20.48 [-53.68, 12.
73]
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Comparison 2. Sensitivity analysis: individual RCTs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality at end of trial 5 4193 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.45, 1.17]
1.1 Normotensive 3 3518 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.40, 1.12]
1.2 Hypertensive 2 675 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.34, 4.24]
2 Cardiovascular mortality at end
of trial
2 675 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.29, 2.64]
2.2 Hypertensive 2 675 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.29, 2.64]
3 Cardiovascular events at end of
trial
3 1416 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.57, 1.30]
3.1 Hypertensives 3 1416 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.57, 1.30]
Analysis 1.1. Comparison 1 Reduced salt versus control, Outcome 1 All-cause mortality at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 1 All-cause mortality at end of trial
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Normotensive
HPT 1990 1/196 1/196 0.3 % 1.00 [ 0.06, 15.87 ]
TOHP I 1992 6/327 12/417 3.5 % 0.64 [ 0.24, 1.68 ]
TOHP II 1997 16/1191 24/1191 7.9 % 0.67 [ 0.36, 1.25 ]
Subtotal (95% CI) 1714 1804 11.6 % 0.67 [ 0.40, 1.12 ]
Total events: 23 (Intervention), 37 (Control)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Hypertensive
Chang 2006 192/768 312/1213 79.1 % 0.97 [ 0.83, 1.14 ]
CSSS 2007 4/302 4/306 1.3 % 1.01 [ 0.26, 4.01 ]
Kwok 2012 27/204 25/225 7.8 % 1.19 [ 0.72, 1.98 ]
Morgan 1978 1/34 0/33 0.2 % 2.91 [ 0.12, 69.08 ]
Subtotal (95% CI) 1308 1777 88.4 % 1.00 [ 0.86, 1.15 ]
Total events: 224 (Intervention), 341 (Control)
Heterogeneity: Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
0.01 0.1 1 10 100
Intervention Control
(Continued . . . )
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 3022 3581 100.0 % 0.96 [ 0.83, 1.10 ]
Total events: 247 (Intervention), 378 (Control)
Heterogeneity: Chi2 = 3.18, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 2.12, df = 1 (P = 0.15), I2 =53%
0.01 0.1 1 10 100
Intervention Control
Analysis 1.2. Comparison 1 Reduced salt versus control, Outcome 2 All-cause mortality at longest follow-up.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 2 All-cause mortality at longest follow-up
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Normotensive
HPT 1990 1/196 1/196 2.4 % 1.00 [ 0.06, 15.87 ]
TOHP I 1992 10/327 14/417 29.8 % 0.91 [ 0.41, 2.02 ]
TOHP II 1997 25/1191 28/1191 67.8 % 0.89 [ 0.52, 1.52 ]
Subtotal (95% CI) 1714 1804 100.0 % 0.90 [ 0.58, 1.40 ]
Total events: 36 (Intervention), 43 (Control)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Hypertensive
Chang 2006 192/768 312/1213 74.6 % 0.97 [ 0.83, 1.14 ]
CSSS 2007 4/302 4/306 1.2 % 1.01 [ 0.26, 4.01 ]
Kwok 2012 27/204 25/225 7.3 % 1.19 [ 0.72, 1.98 ]
Morgan 1978 4/35 5/42 1.4 % 0.96 [ 0.28, 3.30 ]
TONE 1998 51/294 50/291 15.5 % 1.01 [ 0.71, 1.44 ]
0.01 0.1 1 10 100
Intervention Control
(Continued . . . )
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 1603 2077 100.0 % 0.99 [ 0.87, 1.14 ]
Total events: 278 (Intervention), 396 (Control)
Heterogeneity: Chi2 = 0.58, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
0.01 0.1 1 10 100
Intervention Control
Analysis 1.3. Comparison 1 Reduced salt versus control, Outcome 3 Cardiovascular mortality at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 3 Cardiovascular mortality at end of trial
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypertensive
Chang 2006 27/768 66/1213 88.1 % 0.65 [ 0.42, 1.00 ]
CSSS 2007 4/302 4/306 6.8 % 1.01 [ 0.26, 4.01 ]
Morgan 1978 2/33 3/34 5.1 % 0.69 [ 0.12, 3.85 ]
Subtotal (95% CI) 1103 1553 100.0 % 0.67 [ 0.45, 1.01 ]
Total events: 33 (Intervention), 73 (Control)
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
0.01 0.1 1 10 100
Intervention Control
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Analysis 1.4. Comparison 1 Reduced salt versus control, Outcome 4 Cardiovascular events at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 4 Cardiovascular events at end of trial
Study or subgroup Reduced salt Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypertensives
Chang 2006 27/768 66/1213 48.7 % 0.65 [ 0.42, 1.00 ]
CSSS 2007 8/302 5/306 4.7 % 1.62 [ 0.54, 4.90 ]
Morgan 1978 3/34 3/33 2.9 % 0.97 [ 0.21, 4.47 ]
TONE 1998 36/370 46/371 43.7 % 0.78 [ 0.52, 1.18 ]
Total (95% CI) 1474 1923 100.0 % 0.76 [ 0.57, 1.01 ]
Total events: 74 (Reduced salt), 120 (Control)
Heterogeneity: Chi2 = 2.45, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Intervention Control
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Analysis 1.5. Comparison 1 Reduced salt versus control, Outcome 5 Cardiovascular disease events at
longest follow-up.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 5 Cardiovascular disease events at longest follow-up
Study or subgroup Reduced salt Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Normotensive
TOHP I 1992 17/321 32/311 12.7 % 0.51 [ 0.29, 0.91 ]
TOHP II 1997 71/938 80/935 39.0 % 0.88 [ 0.65, 1.20 ]
Subtotal (95% CI) 1259 1246 51.7 % 0.71 [ 0.42, 1.20 ]
Total events: 88 (Reduced salt), 112 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.71, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Hypertensive
Chang 2006 27/768 66/1213 20.6 % 0.65 [ 0.42, 1.00 ]
TONE 1998 36/370 46/371 23.1 % 0.78 [ 0.52, 1.18 ]
Morgan 1978 2/35 2/42 1.2 % 1.20 [ 0.18, 8.09 ]
CSSS 2007 8/302 5/306 3.5 % 1.62 [ 0.54, 4.90 ]
Subtotal (95% CI) 1475 1932 48.3 % 0.77 [ 0.57, 1.02 ]
Total events: 73 (Reduced salt), 119 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
Total (95% CI) 2734 3178 100.0 % 0.77 [ 0.63, 0.95 ]
Total events: 161 (Reduced salt), 231 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.30, df = 5 (P = 0.38); I2 =6%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
0.01 0.1 1 10 100
Intervention Control
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Analysis 1.6. Comparison 1 Reduced salt versus control, Outcome 6 Systolic blood pressure at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 6 Systolic blood pressure at end of trial
Study or subgroup Reduced salt Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensive
HPT 1990 174 -2.8 (6.6) 177 -2.9 (6.6) 24.3 % 0.10 [ -1.28, 1.48 ]
TOHP I 1992 304 -5.1 (7.9) 395 -3 (8.3) 25.7 % -2.10 [ -3.31, -0.89 ]
TOHP II 1997 515 -0.7 (9) 514 0.6 (8.5) 26.8 % -1.30 [ -2.37, -0.23 ]
Subtotal (95% CI) 993 1086 76.8 % -1.15 [ -2.32, 0.02 ]
Heterogeneity: Tau2 = 0.68; Chi2 = 5.57, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 1.92 (P = 0.055)
2 Hypertensive
CSSS 2007 302 -4 (0) 306 3 (0) Not estimable
Morgan 1978 31 -5.5 (22.3) 31 -4 (22.3) 1.6 % -1.50 [ -12.60, 9.60 ]
TONE 1998 317 -4.6 (11.3) 296 -0.4 (10.5) 21.6 % -4.20 [ -5.93, -2.47 ]
Subtotal (95% CI) 650 633 23.2 % -4.14 [ -5.84, -2.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.75 (P < 0.00001)
Total (95% CI) 1643 1719 100.0 % -1.79 [ -3.23, -0.36 ]
Heterogeneity: Tau2 = 1.70; Chi2 = 15.50, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 8.04, df = 1 (P = 0.00), I2 =88%
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Analysis 1.7. Comparison 1 Reduced salt versus control, Outcome 7 Diastolic blood pressure at end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 7 Diastolic blood pressure at end of trial
Study or subgroup Reduced salt Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensive
HPT 1990 174 -2.8 (9.2) 177 -2.9 (9.3) 14.3 % 0.10 [ -1.84, 2.04 ]
TOHP I 1992 304 -4.4 (5.71) 395 -3.2 (5.8) 29.4 % -1.20 [ -2.06, -0.34 ]
TOHP II 1997 515 -3 (6.5) 514 -2.4 (7) 30.0 % -0.60 [ -1.43, 0.23 ]
Subtotal (95% CI) 993 1086 73.7 % -0.80 [ -1.37, -0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
2 Hypertensive
Morgan 1978 31 -5 (11.1) 31 2 (11.1) 2.6 % -7.00 [ -12.53, -1.47 ]
TONE 1998 317 -2.2 (8) 296 -0.2 (7) 23.8 % -2.00 [ -3.19, -0.81 ]
Subtotal (95% CI) 348 327 26.3 % -3.74 [ -8.41, 0.93 ]
Heterogeneity: Tau2 = 8.34; Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 1341 1413 100.0 % -1.17 [ -2.08, -0.26 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 9.51, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 1.50, df = 1 (P = 0.22), I2 =33%
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Analysis 1.8. Comparison 1 Reduced salt versus control, Outcome 8 Urinary sodium excretion at end of
trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 1 Reduced salt versus control
Outcome: 8 Urinary sodium excretion at end of trial
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensive
HPT 1990 143 -15.96 (68.2) 155 0 (71) 16.7 % -15.96 [ -31.77, -0.15 ]
TOHP I 1992 232 -55.2 (76.9) 330 -11.3 (77.7) 17.2 % -43.90 [ -56.87, -30.93 ]
TOHP II 1997 470 -50.9 (86.3) 482 -10.5 (88.5) 17.4 % -40.40 [ -51.50, -29.30 ]
Subtotal (95% CI) 845 967 51.3 % -34.19 [ -49.61, -18.78 ]
Heterogeneity: Tau2 = 139.51; Chi2 = 8.20, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 4.35 (P = 0.000014)
2 Hypertensive
Kwok 2012 204 0.2 (2.5) 225 -0.2 (3) 18.2 % 0.40 [ -0.12, 0.92 ]
Morgan 1978 109 157 (87) 58 180 (120) 12.7 % -23.00 [ -57.94, 11.94 ]
TONE 1998 319 -45 (55.8) 320 -5 (50) 17.8 % -40.00 [ -48.22, -31.78 ]
Subtotal (95% CI) 632 603 48.7 % -20.48 [ -53.68, 12.73 ]
Heterogeneity: Tau2 = 770.80; Chi2 = 94.21, df = 2 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 1477 1570 100.0 % -27.21 [ -49.85, -4.57 ]
Heterogeneity: Tau2 = 733.39; Chi2 = 193.72, df = 5 (P<0.00001); I2 =97%
Test for overall effect: Z = 2.36 (P = 0.019)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 2.1. Comparison 2 Sensitivity analysis: individual RCTs, Outcome 1 All-cause mortality at end of
trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 2 Sensitivity analysis: individual RCTs
Outcome: 1 All-cause mortality at end of trial
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Normotensive
HPT 1990 1/196 1/196 3.0 % 1.00 [ 0.06, 15.87 ]
TOHP I 1992 6/327 12/417 24.4 % 0.64 [ 0.24, 1.68 ]
TOHP II 1997 16/1191 24/1191 58.2 % 0.67 [ 0.36, 1.25 ]
Subtotal (95% CI) 1714 1804 85.6 % 0.67 [ 0.40, 1.12 ]
Total events: 23 (Intervention), 37 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Hypertensive
CSSS 2007 4/302 4/306 12.1 % 1.01 [ 0.26, 4.01 ]
Morgan 1978 1/34 0/33 2.3 % 2.91 [ 0.12, 69.08 ]
Subtotal (95% CI) 336 339 14.4 % 1.20 [ 0.34, 4.24 ]
Total events: 5 (Intervention), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 2050 2143 100.0 % 0.73 [ 0.45, 1.17 ]
Total events: 28 (Intervention), 41 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
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Analysis 2.2. Comparison 2 Sensitivity analysis: individual RCTs, Outcome 2 Cardiovascular mortality at
end of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 2 Sensitivity analysis: individual RCTs
Outcome: 2 Cardiovascular mortality at end of trial
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Hypertensive
CSSS 2007 4/302 4/306 58.5 % 1.01 [ 0.25, 4.09 ]
Morgan 1978 2/33 3/34 41.5 % 0.67 [ 0.10, 4.27 ]
Total (95% CI) 335 340 100.0 % 0.87 [ 0.29, 2.64 ]
Total events: 6 (Intervention), 7 (Control)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Sensitivity analysis: individual RCTs, Outcome 3 Cardiovascular events at end
of trial.
Review: Reduced dietary salt for the prevention of cardiovascular disease
Comparison: 2 Sensitivity analysis: individual RCTs
Outcome: 3 Cardiovascular events at end of trial
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypertensives
CSSS 2007 8/302 5/306 9.9 % 1.64 [ 0.53, 5.07 ]
Morgan 1978 3/34 3/33 5.7 % 0.97 [ 0.18, 5.18 ]
TONE 1998 36/370 46/371 84.5 % 0.76 [ 0.48, 1.21 ]
Total (95% CI) 706 710 100.0 % 0.86 [ 0.57, 1.30 ]
Total events: 47 (Intervention), 54 (Control)
Heterogeneity: Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategies 2008
The Cochrane Library (2008, Issue 4)
Results for CENTRAL, Health Technology Assessment (HTA) and Database of Abstracts of Reviews of Effect (DARE)
Search date: 3 November 2008
#1 MeSH descriptor Heart Arrest explode all trees
#2 (cardiac NEAR/3 arrest*):ti,ab,kw
#3 (heart NEAR/3 arrest*):ti,ab,kw
#4 (cardiopulmonary NEAR/3 arrest*):ti,ab,kw
#5 (sudden NEAR/3 death):ti,ab,kw
#6 asystole*:ti,ab,kw
#7 (myocard* NEAR/2 contract*):ti,ab,kw
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 (death* or died or dead or fatal*):ti,ab
#10 mortality:ti,ab.
#11 (#9 OR #10)
#12 MeSH descriptor Cerebrovascular Disorders explode all trees
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#13 (stroke* or poststroke* or cva*):ti,ab
#14 (cerebrovascular* or (cerebral adj vascular)):ti,ab
#15 (cerebral or cerebellar or brain* or vertebrobasilar):ti,ab
#16 (infarct* or isch*emi* or thrombo* or emboli* or apoplexy):ti,ab
#17 (cerebral or intracerebral or intracranial or brain* or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid):ti,ab
#18 (haemorrhage or hemorrhage or bleed* or haematoma or hematoma or aneurysm):ti,ab
#19 (#15 AND #16)
#20 (#17 AND #18)
#21 (trans* isch*emic attack*):ti,ab
#22 brain attack:ti,ab
#23 MeSH descriptor Hemiplegia explode all trees
#24 (hemipleg* or hemipar* or post NEXT stroke):ti,ab
#25 (#21 OR #22 OR #23 OR #24)
#26 (#12 OR #13 OR #14 OR #19 OR #20 OR #25)
#27 MeSH descriptor Intermittent Claudication explode all trees
#28 claudica*:ti,ab
#29 MeSH descriptor Peripheral Vascular Diseases explode all trees
#30 MeSH descriptor Vascular Diseases, this term only
#31 (peripher* NEAR/3 (occlu* or arteri* or vascular)):ti,ab
#32 (arterial NEAR/3 (obstruct* or occlus*)):ti,ab
#33 MeSH descriptor Arteriosclerosis Obliterans, this term only
#34 MeSH descriptor Atherosclerosis, this term only
#35 MeSH descriptor Arterial Occlusive Diseases, this term only
#36 ((leg or limb) NEAR/3 (isch*emia or occlusi*)):ti,ab
#37 (arteriosclerosis or atherosclerosis):ti,ab
#38 MeSH descriptor Femoral Artery, this term only
#39 MeSH descriptor Popliteal Artery, this term only
#40 MeSH descriptor Iliac Artery, this term only
#41 ((femoral or renal or iliac) NEAR/3 artery):ti,ab
#42 (occlu* or obstruct*):ti,ab
#43 (#38 OR #39 OR #40 OR #41)
#44 (#42 AND #43)
#45 (#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37)
#46 (#44 OR #45)
#47 MeSH descriptor Heart Failure explode all trees
#48 MeSH descriptor Myocardial Ischemia explode all trees
#49 angina:ti,ab
#50 (angor pectoris):ti,ab
#51 myocard*:ti,ab
#52 MeSH descriptor Ventricular Dysfunction explode all trees
#53 (ventricular NEAR/2 failure):ti,ab
#54 revascular*:ti,ab
#55 (isch*mi* NEAR/3 heart):ti,ab,kw
#56 coronary:ti,ab,kw
#57 MeSH descriptor Angioplasty explode all trees
#58 MeSH descriptor Angioplasty, Transluminal, Percutaneous Coronary, this term only
#59 (PTCA or angioplast*):ti,ab
#60 MeSH descriptor Myocardial Revascularization, this term only
#61 stenocardia*:ti,ab
#62 (heart NEAR/3 decompensation):ti,ab
#63 MeSH descriptor Myocardial Infarction explode all trees
#64 (heart NEAR/3 infarc*):ti,ab
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#65 (heart NEAR/3 failure):ti,ab,kw
#66 cardiac*:ti,ab
#67 CABG:ti,ab
#68 MeSH descriptor Coronary Artery Bypass explode all trees
#69 (heart NEAR/3 bypass):ti,ab,kw
#70 (#47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60)
#71 (#61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69)
#72 (#70 OR #71)
#73 (cardiovascular NEAR/3 (outcome* or morbidity or event*)):ti,ab,kw
#74 (hospital* or admission*):ti,ab
#75 (#73 OR #74)
#76 (#8 OR #11 OR #26 OR #46 OR #72 OR #75)
#77 MeSH descriptor Sodium, Dietary explode all trees
#78 MeSH descriptor Diet, Sodium-Restricted explode all trees
#79 MeSH descriptor Sodium, this term only
#80 MeSH descriptor Sodium Chloride explode all trees
#81 (#79 OR #80)
#82 (restrict* or low* or reduc* or intak* or added or diet):ti,ab
#83 (consum* or excess* or increas* or high*):ti,ab
#84 (#82 OR #83)
#85 (#84 AND #81)
#86 (urin* or excret*):ti,ab
#87 (#80 AND #86)
#88 (restrict* NEAR/3 (salt or sodium)):ti,ab,kw
#89 (low* NEAR/3 (salt or sodium)):ti,ab,kw
#90 (reduc* NEAR/3 (salt or sodium)):ti,ab,kw
#91 (intak* NEAR/3 (salt or sodium)):ti,ab,kw
#92 (change NEAR/3 (salt or sodium)):ti,ab,kw
#93 (consum* NEAR/3 (salt or sodium)):ti,ab,kw
#94 (excess* NEAR/3 (salt or sodium)):ti,ab,kw
#95 (sodium NEAR/3 (urin* or excret*)):ti,ab,kw
#96 (increas* NEAR/3 (salt or sodium)):ti,ab,kw
#97 (high* NEAR/3 (salt or sodium)):ti,ab,kw
#98 (added NEAR/3 (salt or sodium or food)):ti,ab,kw
#99 (diet* and (salt or sodium)):ti,ab,kw
#100 (#77 OR #78 OR #85 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 OR #
98 OR #99)
#101 (#76 AND #100)
Ovid MEDLINE(R) 1950 to October Week 4 2008
Search date: 29 October 2008
1 Randomized controlled trial.pt.
2 randomized controlled trial/
3 (random$ or placebo$).ti,ab,sh.
4 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).tw,sh.
5 or/1-4
6 “controlled clinical trial”.pt.
7 (retraction of publication or retracted publication).pt.
8 6 or 7 or 5
9 exp Sodium, Dietary/
10 exp Diet, Sodium-Restricted/
11 Sodium/
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12 Sodium Chloride/
13 11 or 12
14 (restrict* or low* or reduc* or intak* or added).tw. or diet*.mp.
15 (consum* or excess* or increas* or high*).tw.
16 14 or 15
17 13 and 16
18 (urin* or excret*).tw.
19 12 and 18
20 (restrict* adj3 (salt or sodium)).mp.
21 (low* adj3 (salt or sodium)).mp.
22 (reduc* adj3 (salt or sodium)).mp.
23 (intak* adj3 (salt or sodium)).mp.
24 (change adj3 (salt or sodium)).mp.
25 (consum* adj3 (salt or sodium)).mp.
26 (excess* adj3 (salt or sodium)).mp.
27 (sodium adj3 (urin* or excret*)).mp.
28 (increas* adj3 (salt or sodium)).mp.
29 (high* adj3 (salt or sodium)).mp.
30 (added adj3 (salt or sodium or food)).mp.
31 (diet* and (salt or sodium)).tw.
32 9 or 10 or 17 or 19 or (or/20-31)
33 exp Heart Arrest/
34 (cardiac adj3 arrest*).mp.
35 (heart adj3 arrest*).mp.
36 (cardiopulmonary adj3 arrest*).mp.
37 (sudden adj3 death).mp.
38 asystole*.mp.
39 (myocard* adj2 contract*).mp.
40 or/33-39
41 (death* or died or dead or fatal*4).ti,ab.
42 mortality.ti,ab.
43 41 or 42
44 exp Cerebrovascular Disorders/
45 (stroke* or poststroke* or cva*).tw.
46 (cerebrovascular* or (cerebral adj vascular)).tw.
47 (cerebral or cerebellar or brain* or vertebrobasilar).tw.
48 (infarct* or isch?emi* or thrombo* or emboli* or apoplexy).tw.
49 (cerebral or intracerebral or intracranial or brain$ or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid).tw.
50 (haemorrhage or hemorrhage or bleed$ or haematoma or hematoma or aneurysm).tw.
51 48 and 47
52 49 and 50
53 trans* isch?emic attack*.tw.
54 brain attack.tw.
55 hemiplegia/
56 (hemipleg* or hemipar* or post-stroke).tw.
57 54 or 55 or 56 or 53
58 51 or 44 or 52 or 46 or 57 or 45
59 Intermittent Claudication/
60 claudica*.ti,ab.
61 exp Peripheral Vascular Diseases/
62 Vascular Diseases/
63 (peripher* adj3 (occlu* or arteri* or vascular)).ti,ab.
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64 (arterial adj3 (obstruct* or occlus*)).ti,ab.
65 Arteriosclerosis Obliterans/
66 Atherosclerosis/
67 ARTERIAL OCCLUSIVE DISEASES/
68 ((leg or limb) adj3 (isch?emia or occlusi*)).ti,ab.
69 (arteriosclerosis or atherosclerosis).ti,ab.
70 Femoral Artery/
71 POPLITEAL ARTERY/
72 ILIAC ARTERY/
73 ((femoral or renal or iliac) adj3 artery).ti,ab.
74 (occlu* or obstruct*).ti,ab.
75 73 or 72 or 71 or 70
76 75 and 74
77 or/59-69
78 76 or 77
79 40 or 43 or 58 or 78
80 exp Heart Failure/
81 exp Myocardial Ischemia/
82 angina.tw.
83 angor pectoris.tw.
84 myocard*.tw.
85 Ventricular Dysfunction/
86 (ventricular adj2 failure).tw.
87 revascular*.ti,ab.
88 (isch?mi* adj3 heart).ti,ab,sh.
89 coronary.ti,ab,sh.
90 exp Angioplasty/
91 Angioplasty, Transluminal, Percutaneous Coronary/
92 (PTCA or angioplast*).tw.
93 Myocardial Revascularization/
94 stenocardia*.tw.
95 (heart adj3 decompensation).tw.
96 exp Myocardial Infarction/
97 (heart adj3 infarc*).tw.
98 (heart adj3 failure).ti,ab,sh.
99 cardiac*.tw.
100 CABG.tw.
101 exp coronary artery bypass/
102 (heart adj3 bypass).tw,sh.
103 or/80-102
104 (cardiovascular adj3 (outcome* or morbidity or event*)).mp. [mp=title, original title, abstract, name of substance word, subject
heading word]
105 (hospital* or admission*).tw.
106 104 or 105
107 103 or 106 or 58 or 78 or 43 or 40
108 32 and 107
109 (animals not humans).sh.
110 exp Case Reports/
111 letter.pt.
112 (news or editorial).pt.
113 111 or 110 or 112
114 108 not 113
115 114 not 109
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116 8 and 115
EMBASE OVID SP <1980 to 2008 Week 43>
Search date: 30 October 2008
1 sodium intake/
2 sodium restriction/
3 Sodium/
4 Sodium Chloride/
5 3 or 4
6 (restrict* or low* or reduc* or intak* or added).tw. or diet*.mp.
7 (consum* or excess* or increas* or high*).tw.
8 6 or 7
9 5 and 8
10 (urin* or excret*).tw.
11 4 and 10
12 (restrict* adj3 (salt or sodium)).mp.
13 (low* adj3 (salt or sodium)).mp.
14 (reduc* adj3 (salt or sodium)).mp.
15 (intak* adj3 (salt or sodium)).mp.
16 (change adj3 (salt or sodium)).mp.
17 (consum* adj3 (salt or sodium)).mp.
18 (excess* adj3 (salt or sodium)).mp.
19 (sodium adj3 (urin* or excret*)).mp.
20 (increas* adj3 (salt or sodium)).mp.
21 (high* adj3 (salt or sodium)).mp.
22 (added adj3 (salt or sodium or food)).mp.
23 (diet* and (salt or sodium)).tw.
24 1 or 2 or 9 or 11 or (or/12-23)
25 exp Heart Arrest/
26 (cardiac adj3 arrest*).mp.
27 (heart adj3 arrest*).mp.
28 (cardiopulmonary adj3 arrest*).mp.
29 (sudden adj3 death).mp.
30 asystole*.mp.
31 (myocard* adj2 contract*).mp.
32 or/25-31
33 (death* or died or dead or fatal*4).ti,ab.
34 mortality.ti,ab.
35 33 or 34
36 exp Cerebrovascular Disease/
37 (stroke* or poststroke* or cva*).tw.
38 (cerebrovascular* or (cerebral adj vascular)).tw.
39 (cerebral or cerebellar or brain* or vertebrobasilar).tw.
40 (infarct* or isch?emi* or thrombo* or emboli* or apoplexy).tw.
41 (cerebral or intracerebral or intracranial or brain$ or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid).tw.
42 (haemorrhage or hemorrhage or bleed$ or haematoma or hematoma or aneurysm).tw.
43 40 and 39
44 41 and 42
45 trans* isch?emic attack*.tw.
46 brain attack.tw.
47 hemiplegia/
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48 (hemipleg* or hemipar* or post-stroke).tw.
49 46 or 47 or 48 or 45
50 43 or 36 or 44 or 38 or 49 or 37
51 Intermittent Claudication/
52 claudica*.ti,ab.
53 exp Peripheral Vascular Disease/
54 Vascular Disease/
55 (peripher* adj3 (occlu* or arteri* or vascular)).ti,ab.
56 (arterial adj3 (obstruct* or occlus*)).ti,ab.
57 Arteriosclerosis Obliterans/
58 Atherosclerosis/
59 Peripheral Occlusive Artery Disease/
60 ((leg or limb) adj3 (isch?emia or occlusi*)).ti,ab.
61 (arteriosclerosis or atherosclerosis).ti,ab.
62 Femoral Artery/
63 POPLITEAL ARTERY/
64 ILIAC ARTERY/
65 ((femoral or renal or iliac) adj3 artery).ti,ab.
66 (occlu* or obstruct*).ti,ab.
67 65 or 64 or 63 or 62
68 67 and 66
69 or/51-61
70 68 or 69
71 exp Heart Failure/
72 exp Heart Muscle Ischemia/
73 angina.tw.
74 angor pectoris.tw.
75 myocard*.tw.
76 Heart Ventricle Function/
77 (ventricular adj2 failure).tw.
78 revascular*.ti,ab.
79 (isch?mi* adj3 heart).ti,ab,sh.
80 coronary.ti,ab,sh.
81 exp Angioplasty/
82 exp Transluminal Coronary Angioplasty/
83 (PTCA or angioplast*).tw.
84 exp Heart Muscle Revascularization/
85 stenocardia*.tw.
86 (heart adj3 decompensation).tw.
87 exp Heart Infarction/
88 (heart adj3 infarc*).tw.
89 (heart adj3 failure).ti,ab,sh.
90 cardiac*.tw.
91 CABG.tw.
92 exp Coronary Artery Bypass Graft/
93 (heart adj3 bypass).tw,sh.
94 or/71-93
95 (cardiovascular adj3 (outcome* or morbidity or event*)).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name]
96 (hospital* or admission*).tw.
97 95 or 96
98 94 or 97 or 50 or 70 or 35 or 32
99 24 and 98
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100 ((animal$ or Nonhuman$) not human$).sh,hw.
101 letter.pt.
102 editorial.pt.
103 102 or 101 or 100
104 99 not 103
105 Randomized Controlled Trial/
106 Single Blind Procedure/
107 Double Blind Procedure/
108 Crossover Procedure/
109 105 or 106 or 107 or 108
110 (random$ or factorial$ or crossover$ or placebo$ or (cross adj over) or assign$).ti,ab.
111 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).ti,ab.
112 controlled clinical trial*.ti,ab.
113 112 or 110 or 111 or 109
114 104 and 113
PsycINFO (OVID) 1806 to October Week 4 2008
1 (random$ or placebo$ or rct).tw,sh.
2 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).tw,sh.
3 (“2000” or treatment outcome clinical trial).md.
4 ((retract$ or withdraw$) adj (public$ or article$)).tw.
5 or/1-4
6 Sodium/
7 (diet and (salt or sodium)).mp.
8 (restrict* adj3 (salt or sodium)).mp.
9 (low* adj3 (salt or sodium)).mp.
10 (reduc* adj3 (salt or sodium)).mp.
11 (intak* adj3 (salt or sodium)).mp.
12 (change adj3 (salt or sodium)).mp.
13 (consum* adj3 (salt or sodium)).mp.
14 (excess* adj3 (salt or sodium)).mp.
15 (sodium adj3 (urin* or excret*)).mp.
16 (increas* adj3 (salt or sodium)).mp.
17 (high* adj3 (salt or sodium)).mp.
18 (added adj3 (salt or sodium or food)).mp.
19 or/6-18
20 exp Heart Arrest/
21 exp heart disorders/
22 (cardiac adj3 arrest*).mp.
23 (heart adj3 arrest*).mp.
24 (cardiopulmonary adj3 arrest*).mp.
25 (sudden adj3 death).mp.
26 asystole*.mp.
27 (myocard* adj2 contract*).mp.
28 or/20-27
29 (death* or died or dead or fatal*4).ti,ab.
30 mortality.ti,ab.
31 29 or 30
32 exp Cerebrovascular Disorders/
33 (stroke* or poststroke* or cva*).tw.
34 (cerebrovascular* or (cerebral adj vascular)).tw.
35 (cerebral or cerebellar or brain* or vertebrobasilar).tw.
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36 (infarct* or isch?emi* or thrombo* or emboli* or apoplexy).tw.
37 (cerebral or intracerebral or intracranial or brain$ or parenchymal or intraventricular or cerebellar or infratentorial or supratentorial
or subarachnoid).tw.
38 (haemorrhage or hemorrhage or bleed$ or haematoma or hematoma or aneurysm).tw.
39 36 and 35
40 37 and 38
41 32 or 33 or 34 or 39 or 40
42 trans* isch?emic attack*.tw.
43 brain attack.tw.
44 hemiplegia/
45 (hemipleg* or hemipar* or post-stroke).tw.
46 43 or 44 or 45 or 42
47 claudica*.ti,ab.
48 (peripher* adj3 (occlu* or arteri* or vascular)).ti,ab.
49 (arterial adj3 (obstruct* or occlus*)).ti,ab.
50 Atherosclerosis/
51 ((leg or limb) adj3 (isch?emia or occlusi*)).ti,ab.
52 (arteriosclerosis or atherosclerosis).ti,ab.
53 ((femoral or renal or iliac) adj3 artery).ti,ab.
54 (occlu* or obstruct*).ti,ab.
55 or/47-54
56 Heart Failure.mp.
57 ischemia/ and myocard$.tw.
58 angina.tw.
59 angor pectoris.tw.
60 myocard*.tw.
61 Ventricular Dysfunction/
62 (ventricular adj2 failure).tw.
63 revascular*.ti,ab.
64 (isch?mi* adj3 heart).ti,ab,sh.
65 coronary.ti,ab,sh.
66 heart surgery/
67 (PTCA or angioplast*).tw.
68 stenocardia*.tw.
69 (heart adj3 decompensation).tw.
70 exp Myocardial Infarction/
71 (heart adj3 infarc*).tw.
72 (heart adj3 failure).ti,ab,sh.
73 cardiac*.tw.
74 CABG.tw.
75 (heart adj3 bypass).tw,sh.
76 or/56-75
77 (cardiovascular adj3 (outcome* or morbidity or event*)).mp. [mp=title, abstract, heading word, table of contents, key concepts]
78 (hospital* or admission*).tw.
79 77 or 78
80 editorial.dt.
81 letter.dt.
82 80 or 81
83 28 or 31 or 41 or 46 or 55 or 76 or 79
84 83 and 19
85 84 and 5
86 85 not 82
87 86
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88 limit 87 to human
CINAHL
WEB 2.0
Search date: 3 November 2008
1 SODIUM CHLORIDE, DIETARY/ OR DIET, SODIUM-RESTRICTED/
2 SODIUM/
3 SODIUM CHLORIDE/
4 ((restrict* OR low* OR reduc* OR intak* OR added) OR diet*).ti,ab
5 ((consum* OR excess* OR increas* OR high*)).ti,ab
6 4 OR 5
7 6 AND (2 or 3)
8 ((urin* OR excret*)).ti,ab
9 3 AND 8
12 ((restrict* AND (salt OR sodium))).ti,ab
13 ((low* AND (salt OR sodium))).ti,ab
14 ((reduc* AND (salt OR sodium))).ti,ab
15 ((intak* AND (salt OR sodium))).ti,ab
16 ((change AND (salt OR sodium))).ti,ab
17 ((consum* AND (salt OR sodium))).ti,ab
18 ((excess* AND (salt OR sodium))).ti,ab
19 ((sodium AND (urin* OR excret*))).ti,ab
20 ((increas* AND (salt OR sodium))).ti,ab
21 ((high* AND (salt OR sodium))).ti,ab
22 ((added AND (salt OR sodium OR food))).ti,ab
23 ((diet* AND (salt OR sodium))).ti,ab
24 1 OR 7 OR 9 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23
25 24 [Limit to: (Publication Type Clinical Trial or Systematic Review)]
26 ((placebo* OR random* OR rct)).ti,ab
27 (((singl* OR double* OR triple* OR treble*) AND (blind* OR mask*))).ti,ab
28 ((controlled clinical trial)).ti,ab
29 26 OR 27 OR 28
30 24 AND 29
31 25 OR 30 [Limit to: (Publication Type Clinical Trial or Systematic Review)]
Appendix 2. Search strategies 2013
CENTRAL
#1 MeSH descriptor: [Sodium, Dietary] explode all trees
#2 MeSH descriptor: [Diet, Sodium-Restricted] this term only
#3 (restrict* near/3 (salt or sodium))
#4 (low* near/3 (salt or sodium))
#5 (reduc* near/3 (salt or sodium))
#6 (intak* near/3 (salt or sodium))
#7 (change near/3 (salt or sodium))
#8 (consum* near/3 (salt or sodium))
#9 (excess* near/3 (salt or sodium))
#10 (high* near/3 (salt or sodium))
#11 (diet* and (salt or sodium))
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#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 MeSH descriptor: [Cardiovascular Diseases] explode all trees
#14 cardio* or cardia* or heart* or coronary* or angina* or ventric* or myocard*
#15 pericard* or isch?em* or emboli* or arrhythmi* or thrombo* or atrial next fibrillat*
#16 tachycardi* or endocardi* or sick near/3 sinus
#17 MeSH descriptor: [Stroke] explode all trees
#18 stroke or stokes or cerebrovasc* or apoplexy or cerebral next vascular
#19 brain near/2 accident*
#20 ((brain* or cerebral or lacunar) near/2 infarct*)
#21 MeSH descriptor: [Hypertension] explode all trees
#22 hypertensi* or peripheral next arter* next disease*
#23 ((high or increased or elevated) near/2 blood pressure)
#24 MeSH descriptor: [Hyperlipidemias] explode all trees
#25 hyperlipid* or hyperlip?emia* or hypercholesterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?emia*
#26 MeSH descriptor: [Arteriosclerosis] explode all trees
#27 MeSH descriptor: [Cholesterol] explode all trees
#28 cholesterol
#29 “coronary risk factor*”
#30 MeSH descriptor: [Blood Pressure] this term only
#31 blood pressure
#32 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#33 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
#34 #32 or #33
#35 #12 and #34
MEDLINE
1. exp Sodium, Dietary/
2. Diet, Sodium-Restricted/
3. (restrict* adj3 (salt or sodium)).tw.
4. (low* adj3 (salt or sodium)).tw.
5. (reduc* adj3 (salt or sodium)).tw.
6. (intak* adj3 (salt or sodium)).tw.
7. (change adj3 (salt or sodium)).tw.
8. (consum* adj3 (salt or sodium)).tw.
9. (excess* adj3 (salt or sodium)).tw.
10. (high* adj3 (salt or sodium)).tw.
11. (diet* and (salt or sodium)).tw.
12. or/1-11
13. exp Cardiovascular Diseases/
14. cardio*.tw.
15. cardia*.tw.
16. heart*.tw.
17. coronary*.tw.
18. angina*.tw.
19. ventric*.tw.
20. myocard*.tw.
21. pericard*.tw.
22. isch?em*.tw.
23. emboli*.tw.
24. arrhythmi*.tw.
25. thrombo*.tw.
26. atrial fibrillat*.tw.
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27. tachycardi*.tw.
28. endocardi*.tw.
29. (sick adj sinus).tw.
30. exp Stroke/
31. (stroke or stokes).tw.
32. cerebrovasc*.tw.
33. cerebral vascular.tw.
34. apoplexy.tw.
35. (brain adj2 accident*).tw.
36. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
37. exp Hypertension/
38. hypertensi*.tw.
39. peripheral arter* disease*.tw.
40. ((high or increased or elevated) adj2 blood pressure).tw.
41. exp Hyperlipidemias/
42. hyperlipid*.tw.
43. hyperlip?emia*.tw.
44. hypercholesterol*.tw.
45. hypercholester?emia*.tw.
46. hyperlipoprotein?emia*.tw.
47. hypertriglycerid?emia*.tw.
48. exp Arteriosclerosis/
49. exp Cholesterol/
50. cholesterol.tw.
51. “coronary risk factor* ”.tw.
52. Blood Pressure/
53. blood pressure.tw.
54. or/13-53
55. 12 and 54
56. randomized controlled trial.pt.
57. controlled clinical trial.pt.
58. randomized.ab.
59. placebo.ab.
60. drug therapy.fs.
61. randomly.ab.
62. trial.ab.
63. groups.ab.
64. 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63
65. exp animals/ not humans.sh.
66. 64 not 65
67. 55 and 66
68. (200810* or 200811* or 200812* or 2009* or 2010* or 2011* or 2012* or 2013*).ed.
69. 67 and 68
EMBASE
1. salt intake/
2. sodium restriction/
3. (restrict* adj3 (salt or sodium)).tw.
4. (low* adj3 (salt or sodium)).tw.
5. (reduc* adj3 (salt or sodium)).tw.
6. (intak* adj3 (salt or sodium)).tw.
7. (change adj3 (salt or sodium)).tw.
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8. (consum* adj3 (salt or sodium)).tw.
9. (excess* adj3 (salt or sodium)).tw.
10. (high* adj3 (salt or sodium)).tw.
11. (diet* and (salt or sodium)).tw.
12. or/1-11
13. exp cardiovascular disease/
14. cardio*.tw.
15. cardia*.tw.
16. heart*.tw.
17. coronary*.tw.
18. angina*.tw.
19. ventric*.tw.
20. myocard*.tw.
21. pericard*.tw.
22. isch?em*.tw.
23. emboli*.tw.
24. arrhythmi*.tw.
25. thrombo*.tw.
26. atrial fibrillat*.tw.
27. tachycardi*.tw.
28. endocardi*.tw.
29. (sick adj sinus).tw.
30. exp cerebrovascular disease/
31. (stroke or stokes).tw.
32. cerebrovasc*.tw.
33. cerebral vascular.tw.
34. apoplexy.tw.
35. (brain adj2 accident*).tw.
36. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
37. exp hypertension/
38. hypertensi*.tw.
39. peripheral arter* disease*.tw.
40. ((high or increased or elevated) adj2 blood pressure).tw.
41. exp hyperlipidemia/
42. hyperlipid*.tw.
43. hyperlip?emia*.tw.
44. hypercholesterol*.tw.
45. hypercholester?emia*.tw.
46. hyperlipoprotein?emia*.tw.
47. hypertriglycerid?emia*.tw.
48. exp Arteriosclerosis/
49. exp Cholesterol/
50. cholesterol.tw.
51. “coronary risk factor*”.tw.
52. Blood Pressure/
53. blood pressure.tw.
54. or/13-53
55. 12 and 54
56. random$.tw.
57. factorial$.tw.
58. crossover$.tw.
59. cross over$.tw.
60. cross-over$.tw.
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61. placebo$.tw.
62. (doubl$ adj blind$).tw.
63. (singl$ adj blind$).tw.
64. assign$.tw.
65. allocat$.tw.
66. volunteer$.tw.
67. crossover procedure/
68. double blind procedure/
69. randomized controlled trial/
70. single blind procedure/
71. 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70
72. (animal/ or nonhuman/) not human/
73. 71 not 72
74. 55 and 73
75. (20084* or 20085* or 2009* or 2010* or 2011* or 2012* or 2013*).em.
76. 74 and 75
77. limit 76 to embase
CINAHL
S54 S52 AND S53
S53 EM 20081101-20130401
S52 S33 AND S51
S51 S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50
S50 TX cross-over*
S49 TX crossover*
S48 TX volunteer*
S47 (MH “Crossover Design”)
S46 TX allocat*
S45 TX control*
S44 TX assign*
S43 TX placebo*
S42 (MH “Placebos”)
S41 TX random*
S40 TX (doubl* N1 mask*)
S39 TX (singl* N1 mask*)
S38 TX (doubl* N1 blind*)
S37 TX (singl* N1 blind*)
S36 TX (clinic* N1 trial?)
S35 PT clinical trial
S34 (MH “Clinical Trials+”)
S33 S12 AND S32
S32 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
OR S28 OR S29 OR S30 OR S31
S31 blood pressure
S30 (MH “Blood Pressure”)
S29 “coronary risk factor*”
S28 cholesterol
S27 (MH “Cholesterol+”)
S26 (MH “Arteriosclerosis+”)
S25 hyperlipid* or hyperlip?emia* or hypercholesterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?emia*
S24 (MH “Hyperlipidemia+”)
S23 ((high or increased or elevated) N2 blood pressure)
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S22 hypertensi* or peripheral arter* disease*
S21 (MH “Hypertension+”)
S20 ((brain* or cerebral or lacunar) N2 infarct*)
S19 brain N2 accident*
S18 stroke or stokes or cerebrovasc* or apoplexy or cerebral next vascular
S17 (MH “Stroke+”)
S16 tachycardi* or endocardi* or sick N3 sinus
S15 pericard* or isch?em* or emboli* or arrhythmi* or thrombo* or atrial fibrillat*
S14 cardio* or cardia* or heart* or coronary* or angina* or ventric* or myocard*
S13 (MH “Cardiovascular Diseases+”)
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S11 (diet* and (salt or sodium))
S10 (high* N3 (salt or sodium))
S9 (excess* N3 (salt or sodium))
S8 (consum* N3 (salt or sodium))
S7 (change N3 (salt or sodium))
S6 (intak* N3 (salt or sodium))
S5 (reduc* N3 (salt or sodium))
S4 (low* N3 (salt or sodium))
S3 (restrict* N3 (salt or sodium))
S2 (MH “Diet, Sodium-Restricted”)
S1 (MH “Sodium, Dietary+”)
WH A T ’ S N E W
Last assessed as up-to-date: 1 May 2013.
Date Event Description
1 May 2014 New citation required but conclusions have not changed Two new studies included. Conclusions not changed.
1 May 2014 New search has been performed Searches re-run in May 2013.
H I S T O R Y
Review first published: Issue 7, 2011
Date Event Description
6 June 2013 Amended The Paterna trial has now been retracted and we have removed the data from this trial from the
review
13 March 2013 Amended Doubts have been raised about the integrity of research from the Paterna group. The previously
published results should be discounted for now
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(Continued)
1 September 2011 Amended Amended ’Plain language summary’.
6 July 2011 Amended Corrected typo error in ’Abstract - Results’ section.
C O N T R I B U T I O N S O F A U T H O R S
All the authors were involved in the design of the review.
In the original review:
TM developed the search strategy.
KA and RT selected studies for inclusion, extracted data, carried out data synthesis/analysis and wrote the first draft of the review.
For this update:
NM conducted the searches.
FCT, NM and AJA screened abstracts and selected studies for analysis.
FCT and AJA extracted trial data.
AJA did the analysis and wrote the review.
SE reviewed the data extraction, did the analysis and wrote the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Given the small number of trials included in this review it was not possible to undertake exploration of heterogeneity using stratified
meta-analysis or meta-regression.
N O T E S
Following doubts raised about the integrity of research from the Paterna group and retraction of a publication by this group (Heart
2013), we have now removed this trial and its data from this review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Diet, Sodium-Restricted; Cardiovascular Diseases [mortality; ∗prevention & control]; Hypertension [mortality]; Randomized Con-
trolled Trials as Topic; Sodium Chloride, Dietary [∗administration & dosage]
MeSH check words
Adult; Humans
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